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FUNCTIONAL CHARACTERIZATION OF CRIP1A KNOCKOUT MICE 
By Joanna Caitlin Jacob, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2013 
Major Director: Dana E. Selley, Ph.D., Department of Pharmacology and Toxicology 
 
The CB1 cannabinoid receptor is one of the most highly expressed receptors in the mammalian 
central nervous system (CNS).  It is most densely distributed on pre-synaptic terminals in the 
forebrain, basal ganglia and cerebellum, where it inhibits both excitatory and inhibitory 
neurotransmission.  Recently, two novel proteins were discovered that bind to the CB1 receptor 
C-terminal tail, and termed cannabinoid receptor interacting protein 1a and 1b (CRIP1a and 
CRIP1b). CRIP1a is expressed throughout vertebrates, whereas CRIP1b expression appears to be 
primate-specific. Studies characterizing CRIP1a have thus far been conducted in cellular models 
using over-expression (gain-of-function) approaches, and indicate that CRIP1a inhibits 
constitutive CB1 receptor activity without affecting CB1 receptor expression. However, very little 
is known about the biological function of CRIP1a in the intact CNS. The objective of this thesis 
was to characterize the first CRIP1a knockout mouse line for novel behavioral phenotypes and 
molecular changes in the CNS as a result of the loss of CRIP1a.  The absence of CRIP1a was 
confirmed using both quantitative PCR (qPCR) and Western immunoblot analysis.  CB1 receptor 
levels were found to remain unchanged in CRIP1a knockout (KO) mice when compared to wild 
	  	   xii 
type (WT) littermate controls in the cerebellum, hippocampus and amygdala.  Though high in 
receptor levels, the cerebellum and hippocampus did not display enhanced CB1-mediated G-
protein activity as determined by agonist-stimulated [35S]GTPγS binding.  The amygdala, 
however, produced significant increases in CB1-mediated G-protein activity in response to both 
CP55,940 and Noladin Ether.  This effect was further realized when CRIP1a KO mice produced 
significant anxiolytic-like phenotypes in two models of anxiety: the light:dark box and marble 
burying.  In addition to the anxiolytic-like phenotype, a significant antinociceptive phenotype 
was observed in naïve CRIP1a KO mice.  However, after tetrad analysis with CP55,940 in male 
CRIP1a WT, heterozygous (HET) and KO mice, no significant genotype differences were 
revealed in antinociception, motor coordination or reduced body temperature.  We also 
discovered that the expression of CRIP1a and CB1 receptors is independent of one another in 
brain regions such as the cerebellum, prefrontal cortex and the amygdala.  Our studies were the 
first to investigate CRIP1a function in live animals, and our findings suggest that CRIP1a could be 
a key player in the endocannabinoid system, serving as a promising future pharmacological 
target for studying and treating anxiety disorders. 
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Chapter 1. Introduction 
 
1.1 Cannabinoids and Cannabinoid Receptors  
Cannabis Sativa, or Marijuana, is a plant that has been cultivated by humans for over four 
thousand years for a variety of uses ranging from cooking oil and fibrous material to medicinal 
and recreational purposes (Russo, 2007).  Archeological evidence of medical marijuana use has 
been described in many ancient cultures including the Chinese and Egyptians, most often for 
relief from several types of pain, such as muscle cramps, wounds and inflammation, though 
numerous other uses have been documented.  It is suspected that today’s marijuana strains are a 
domesticated form, derived from the once wild plants whose origins lay in Central Asia.  
Marijuana is comprised of numerous compounds, including phytocannabinoids.  Selective 
breeding has produced strains in which these phytocannabinoid ratios differ, often attributed to 
geographical preferences.  The overall percentage of marijuana’s main psychoactive constituent, 
Δ9-tetrahydrocannabinol (THC) is thought to have changed over the years, with modern strains 
containing higher levels of THC and lower amounts of cannabidiol (CBD) (King et al. 2005).  
CBD is a medically relevant, non-psychoactive cannabinoid compound, shown to exhibit 
neuroprotective and anxiolytic effects.  In the Middle East and northern parts of Africa, 
THC:CBD ratios are often 1:1, however in Europe and North America, THC percentages are 
much higher than CBD (Leggett and Pietschmann, 2008), presumably due largely to its 
recreational use.    
THC was first identified in its pure form in 1964 (Gaoni and Mechoulam, 1964).  Initially, 
cannabinoids were believed to produce membrane perturbation and destabilization due to their 
hydrophobic properties.  It wasn’t until years later, in 1981, when findings reported 
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stereoselective differences between (+) and (-) THC isomers in behavioral tests, thus supporting 
a new concept in which THC acts via a receptor-mediated mechanism (Martin et al., 1981).  
Shortly thereafter, further evidence was published supporting the likelihood of a cannabinoid 
receptor population, which showed various cannabinoids including THC inhibited adenylyl 
cyclase activity in a pertussis-toxin sensitive manner in a cultured mouse neuroblastoma 
(N18TG2) cell line (Howlett et al. 1986).  The presence of cannabinoid receptors in the brain 
was later confirmed using a radiolabeled synthetic cannabinoid, [3H]CP55,940 which bound 
stereoselectively, with high affinity and reached saturation (Devane et al. 1988).  These receptors 
were subsequently cloned and named cannabinoid receptor type 1 (CB1) (Matsuda et al. 1990) 
and cannabinoid receptor type 2 (CB2)  (Gérard et al. 1991; Munro et al. 1993).   
Both CB1 and CB2 receptors are G-protein coupled receptors, and associate with Gi/o G-
protein subunits [see (Howlett et al. 2002) for review].  Upon cannabinoid receptor activation, 
cAMP production is decreased due to the inhibition of adenylyl cyclase via Gαi/o subunits 
(Howlett et al. 1985; Howlett et al. 1986).  Simultaneously, the Gβγ subunits can activate 
inwardly rectifying potassium (GIRK) channels (Mackie et al. 1995; McAllister et al. 1999) and 
decrease the conductance of N- and P/Q-type voltage-gated calcium channels (Mackie and Hille, 
1992; Twitchell et al. 1997).  Collectively, these actions result in a reduction of synaptic vesicle 
fusion at the nerve terminal, inhibiting both excitatory and inhibitory neurotransmitter release.  
In addition, a well-characterized electrophysiological hallmark of CB1 activation in the brain is 
known as depolarization-induced suppression of inhibition (DSI).  First shown to be CB1-
mediated in the cerebellum (Vincent et al. 1992) and confirmed in the hippocampus (Pitler and 
Alger, 1992), DSI leads to hyperpolarization of a repeatedly depolarized neuron, thus 
suppressing successive vesicular fusion and release of γ-Aminobutyric acid (GABA).  This was 
	  	   3 
later shown to be absent in CB1 receptor knockout mice, strengthening the claim that DSI is CB1-
mediated (Ohno-Shosaku et al. 2001).  CB1 receptors also mediate depolarization-induced 
suppression of excitation (DSE), which differs in definition from DSI simply by the fact that it 
describes inhibition of the release of the excitatory neurotransmitter, glutamate, rather than 
GABA.  Evidence for DSE is best characterized in autaptic hippocampal neurons and is 
reportedly mediated by 2-AG activation of CB1 receptors (Straiker et al. 2009).  Furthermore, 
recent studies have shown that DSE is present in other brain regions, such as the lateral 
amygdala, and is mediated by retrograde endocannabinoid signaling at CB1 receptors (Kodirov et 
al. 2010).   
 
1.2 Cannabinoid Receptor Localization.      
CB1 receptors are one of the most prevalent receptor types found in the brain (Herkenham et 
al. 1991), but are also peripherally located (Pertwee et al. 1996).  CB2 receptors have a limited 
presence in the central nervous system, where they are expressed primarily on microglial cells 
(Cabral and Marciano-Cabral, 2005) and neurons (Van Sickle et al., 2005) but also play a 
supporting role in the peripheral immune system (Munro et al. 1993; Carlisle et al. 2005).  
Within the brain, CB1 receptors are most densely expressed in the cerebellum, hippocampus, 
cortex, and basal ganglia (Herkenham et al. 1991; Sim et al. 1996).  The hypothalamus and 
periaqueductal gray each exhibit modest CB1 expression, whereas slightly less expression is seen 
in the spinal cord (Tsou et al. 1998).  It is important to note that CB1 receptor expression is very 
low in the pons and medulla, which are known to be involved in autonomic functions such as 
respiratory and cardiac regulation, and perhaps this provides one explanation as to why an 
absence of life-threatening effects is associated with marijuana (Herkenham et al., 1991).   
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Δ9-THC acts as a partial agonist at CB1 (Sim et al. 1996) and CB2 receptors (Bayewitch et al. 
1996), yet is considered the principal compound responsible for marijuana’s intoxicating effects.  
Known functions of the brain regions exhibiting high CB1 expression levels reflect the 
pharmacological effects (i.e. cannabimimetic effects) often described after marijuana 
consumption, including short-term memory loss, hypothermia, catalepsy, antinociception and 
reduced motor coordination (Hollister, 1986; Dewey, 1986). A behavioral tetrad model was 
developed to screen compounds for cannabimimetic effects in rodents, specifically catalepsy, 
hypothermia, reduced locomotor activity and antinociception (Little et al. 1988, Varvel et al. 
2005).  If the pharmacological effects of a ligand are CB1 receptor-mediated, these effects are 
reversible or blocked by a CB1 antagonist such as rimonabant (also known as SR141716A), and 
are absent in CB1 knockout mice (Compton et al. 1996; Fride, 2002).  
 
1.3 Cannabinoid Ligands 
1.3a. The Endocannabinoids.  The confirmed presence of two cannabinoid receptor types in 
multiple species (see Onaivi et al. 2002 for review), strongly suggested that an endogenous 
system is present.   The search for endogenous ligands led to the discovery of N-arachidonoyl 
ethanolamine in 1992 (Devane et al. 1992).  Commonly referred to as anandamide (AEA), after 
the Sanskrit word for “delight, bliss” ananda, it is synthesized from N-arachidonoyl 
phosphatidylethanolamine (NAPE) by multiple pathways (Wang and Ueda, 2009) and shows 
moderate selectivity for the CB1 receptor.  A second endogenous ligand, 2-arachidonylglycerol 
(2-AG), was reported by two independent laboratories in 1995 (Mechoulam et al. 1995; Sugiura 
et al. 1995).   2-AG is synthesized by cleavage of diacylglycerol (DAG) via diacylglycerol 
lipases (DAGL), and as been shown to bind with similar affinities to CB1 and CB2 receptors and 
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act as a full CB1 agonist (Savinainen et al. 2001).  Anandamide and 2-AG are primarily degraded 
by the enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), 
respectively (Cravatt et al. 1996; Dinh et al. 2002).  Anandamide is broken down into 
arachidonic acid and ethanolamine, while 2-AG is broken down into arachidonic acid and 
glycerol.  Both ligands are equally pertinent when defining the endocannabinoids, though it is 
important to note that 2-AG is present at nmol/g levels compared to pmol/g levels of 
anandamide.  However, levels vary frequently between reports, therefore there may be anywhere 
from a 200 to 1000-fold difference in 2-AG concentrations compared to anandamide (for review, 
see Buczynski and Parsons, 2010).  A third, yet putative, endocannabinoid known as 2-
arachidonyl glyceryl ether, or Noladin Ether, was reported to bind with high affinity and produce 
sedation, hypothermia and mild nociception in mice (Hanuš et al. 2001). Though capable of 
mediating these cannabimimetic effects, its relative efficacy to 2-AG is weak (Sugiura et al. 
1999).  
 
1.3b.  Exogenous cannabinoid ligands.  Marijuana contains hundreds of constituents belonging 
to various classes of compounds including terpenoids, flavonoids, hydrocarbons and steroids 
(ElSohly and Slade, 2005).  It was recently estimated that there are over 85 cannabinoids 
naturally found in marijuana (El-Alfy et al. 2010).  In addition to THC and cannabidiol, 
tetrahydrocannabivarin, cannabigerol and cannabichromene are all phytocannabinoids commonly 
found in many strains of marijuana.  Cannabichromene and cannabigerol are both non-
psychoactive compounds, yet cannabichromene has been shown to be dose-dependently effective 
at reducing inflammation in the lipopolysaccharide-induced paw edema model (DeLong et al. 
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2010).  Tetrahydrocannabivarin has been shown to antagonize the effects of THC at the CB1 
receptor and attenuate its psychoactive effects (Thomas et al. 2005).   
Throughout the years, numerous synthetic cannabinoids have been developed.  Both 
pharmaceutical companies and independent laboratories have synthesized cannabinoid analogs in 
an attempt to further study the various effects of these compounds and potentially circumvent the 
untoward effects of THC.  Analogs that are structurally similar to THC are considered 
“classical”.  One example is HU-210, which has been shown to be at least 100 times more potent 
at the CB1 receptor than THC and has a longer half-life (Felder et al. 1995).  “Non-classical” 
synthetic cannabinoids range from somewhat dissimilar in structure to disparate in structure to 
THC, though they are still quite potent and efficacious at one or both of the cannabinoid 
receptors.  Pfizer produced a bicyclic analog, CP55,940, which is a high-efficacy ligand at both 
CB1 and CB2 receptors, with potencies 100-fold greater than THC in behavioral assays (Wiley et 
al. 1995) and CB1 receptor binding experiments (Gatley et al. 1997).  WIN 55,212-2 (WIN) is a 
non-classical cannabinoid belonging to the aminoalkylindole group and is structurally dissimilar 
to THC.  It also binds potently to CB1 and CB2 receptors in addition to eliciting robust behavioral 
effects (Kuster et al. 1993, Pacher et al. 2006).  
Synthetic cannabinoids are currently being synthesized and introduced as constituents in 
abused herbal blends.  Recently, many of these compounds have elicited widespread clinical 
concern relating to higher addiction liabilities, increased psychosis and even adverse cardiac 
events (Zimmermann et al. 2009, Müller et al. 2010, Mir et al. 2011).  As a method to 
circumvent legal obstacles, these designer compounds, which are capable of mimicking THC’s 
effects, are sprayed onto herbal substances and packaged as herbal incense, such as “spice” or 
“K2”.   Atwood et al. (2010) studied a common constituent of spice, JWH-018, which is now 
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federally regulated by the U.S. government as a schedule I drug.  After applying the compound 
to cultured autaptic hippocampal neurons, significant inhibition of excitatory synaptic currents 
were observed along with rapid induction of CB1 receptor internalization.  JWH-018 was also 
found to be significantly more potent than WIN at CB1 receptors but exhibited similar efficacy.  
These lines of evidence could explain, in part, the ability of potent synthetic cannabinoids to 
elicit strong episodes of psychosis and anxiogenic effects in some users.   
 
1.4 Cannabinoid Receptor Signaling Through G-Protein Activation.    
CB1 and CB2 receptors are structurally consistent with other G-protein coupled receptors 
(GPCRs) and consist of seven transmembrane domains, an intracellular C-terminus and an 
extracellular N-terminus (Matsuda et al. 1990, Munro et al. 1993).  The two cannabinoid 
receptors share an estimated 44% homology overall (Montero et al. 2005), with significant 
variability in the intracellular C-terminus (see Figure 1).  It has been well documented that G-
proteins interact with the C-terminus of the CB1 receptor (Nie and Lewis, 2001) and the third 
intracellular loop, located between transmembrane domains 6 and 7 (Mukhopadhyay and 
Howlett, 2001). 
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Figure 1. Alignment of the cannabinoid receptors and bovine rhodopsin (1F88) amino acid 
sequences. The identical residues shared among all three receptors are highlighted in black. α 
helix and β sheet predictions within the transmembrane regions were carried out by the modeling 
software, Psipred.  The proposed α helix structures are marked in gray, while the proposed β 
sheet structures are underlined.  Phosphorylation sites necessary for desensitization and 
internalization are represented by (*) and (^), respectively.  Underlined in red is the CRIP1a 
binding site.  Figure is adapted from Tuccinardi et al. (2006), Jin et al. (1999), Hsieh et al. (1999) 
and Niehaus et al. (2007).   
Once an agonist binds to the receptor, a conformational change occurs, stabilizing the 
receptor in an active state (Sprang, 1997; Lefkowitz et al. 1993).  Receptor activation triggers a 
signaling cascade, beginning with the stimulation of bound heterotrimeric G-proteins (Figure 2).  
An exchange of GDP for GTP occurs at the Gα subunit, allowing the Gα and Gβγ subunits to 
dissociate both from the receptor and from one another.  This dissociation allows both G-protein 
subunits to implement downstream signaling events. The cycle is eventually terminated due to 
the Gα subunit’s intrinsic GTPase activity.  GTP is dephosphorylated back to GDP, which 
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returns the Gα subunit to its resting state, allowing it to reassociate with both the Gβγ subunit 
and a GPCR (Rockhold, 2002).  
   
Figure 2. G-protein-coupled receptor (GPCR)-mediated G-protein activation. In the inactive 
state, G-proteins exist in the form of an αβγ heterotrimer, with the Gα subunit bound to GDP. 
Upon receptor activation, either by the binding of agonist or constitutively, the receptor changes 
to an active conformation (green), thereby activating G-proteins by promoting the exchange of 
GDP for GTP. The Gα-GTP and Gβγ dimer functionally dissociate from one another and the 
receptor and are free to modulate downstream effectors. The cycle concludes when the GTPase 
activity of the Gα subunit hydrolyses GTP to GDP, allowing the Gα subunit to return to its 
resting confirmation and reassociate with Gβγ. Figure is adapted from Smith et al. (2010).  
 
GPCRs are known to act catalytically (Gilman, 1987), and are capable of signal 
amplification.  This is possible due to the rate at which a GPCR can activate G-proteins, which is 
faster than the rate at which the initially activated G-protein can turn itself off.  G-protein 
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activation can be measured utilizing the [35S]GTPγS binding assay, in which a hydrolysis-
resistant form of GTP is used.  A radioactive sulfur, [35S], replaces an oxygen molecule on the γ 
phosphate, which impedes GTP from being dephosphorylated to GDP.  During incubation with 
ligands of interest and an excess of GDP, the radiolabeled GTPγS molecule readily binds to 
activated Gα subunits and accumulates. This complex now serves as a measure of G-protein 
activation in response to ligand.  Ligand efficacies are often determined using this method, 
including numerous cannabinoid compounds that have been characterized as full, partial or 
inverse agonists at the CB1 receptor.    
A ligand’s efficacy and potency can be measured utilizing a concentration effect curve, 
which provides an Emax and EC50 value, respectively.  Many natural and synthetic cannabinoids 
have been analyzed for their respective efficacies on CB1-mediated G-protein activation, as G-
protein activation is an early event in CB1 receptor-mediated signal transduction.  CP55,940 and 
WIN are examples of high efficacy cannabinoids at the CB1 receptor (Griffin et al. 1998), while 
THC and a more stable anandamide analog, methanandamide, are examples of partial agonists, 
with THC exhibiting low efficacy (Sim et al. 1996, Breivogel et al. 1998).  Anandamide has also 
been shown to bind to CB1 receptors in the cerebellum and produce moderate efficacy relative to 
WIN in agonist-stimulated [35S]GTPγS binding assays (Kearn et al. 1999; Breivogel et al. 1998).  
The CB1 receptor antagonist, SR141716A, also known as rimonabant, was reported to have 
inverse agonist properties (Bouaboula et al. 1997; Landsman et al. 1997), further inhibiting the 
agonist-independent “basal” G-protein activity.  Inverse agonists, by definition, bind to the same 
site as agonists, but produce opposite effects (Figure 3).  This concept is explained in further 
detail below, in Section 1.5.   
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Figure 3. Hypothetical concentration-effect curves diagraming ligand efficacy. The curve with 
the greatest maximal effect represents a full agonist. The second curve represents a partial 
agonist, where its maximal effect lies between 0% and 100% response.  A neutral antagonist 
binds to the receptor, but produces no response; therefore a straight line represents this state 
rather than a curve.  Neutral antagonists may also graphically appear to have a similar response 
as when no agonist is present.  Inverse agonists bind to the receptor and produce an opposite 
effect, in that they can suppress a given measure below the baseline level.  It is thought that 
inverse agonists unmask the level of response specifically mediated by a receptor’s constitutive, 
or basal activity. In all examples, once maximal response is reached, increases in ligand 
concentration produce no further change in response.  
 
1.5 Constitutive G-Protein Coupled Receptor Activity 
Inverse agonists are important tools in assessing the phenomenon known as constitutive 
activity, which is commonly reported in GPCRs.  Constitutive activity is defined by the ability of 
a receptor to spontaneously shift from an inactive state, R, to an active state, R*, in the absence 
of an agonist (Figure 4). Currently, inverse agonists are thought to maintain the receptor in a 
closed conformation, leading to their ability to measurably reduce G-protein activity below tonic, 
or “basal” levels (Braestrup et al. 1983, de Ligt et al. 2000).  Constitutive activity was first 
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observed in GPCRs by Costa and Hertz (1989), when inverse agonist properties were discovered 
in delta opioid receptors.  Rinaldi et al. (1994) first observed inverse agonist effects in CB1 
receptors after the development of SR141716A.  One criticism of these results, however, is that 
ligands such as SR141716A could be mediating endogenous “tone”, rather than affecting the 
receptor state itself.  In an attempt to further demonstrate this finding, studies were performed on 
various populations of GPCRs shown to be capable of spontaneous receptor activation by using 
cell lines or cultured neuronal populations that do not contain the related endogenous ligands.  
One such study specifically evaluated superior cervical ganglion (SCG) neurons injected with 
CB1 cRNA and found that the CB1 antagonist, SR141716A (or rimonabant), exhibited inverse 
agonist activity by reversing tonic inhibition of N-type voltage-gated Ca2+ channels, thus 
increasing their activity and suggesting that CB1 receptors display some level of constitutive 
activity (Pan et al. 1998).  CB1 receptor transfected cell lines provide a highly uniform and 
simplified model to compare inverse agonist and neutral antagonist actions.  Conclusions drawn 
from those studies can therefore be directly related to the CB1 receptor, since it is artificially 
expressed at higher levels compared to other GPCRs within these cell lines.  [35S]GTPγS binding 
has long been used as a method of identifying inverse agonist properties.  Cell lines transfected 
with mouse or human CB1 receptors have both exhibited measurable levels of constitutive 
activity as a result of SR141716A application in [35S]GTPγS binding (Bouaboula et al. 1995; 
Landsman et al. 1997; MacLennan et al. 1998) suggesting it is a conserved function of the 
receptor and not an artifact of the species or model studied.  However, similar studies performed 
in rat brain have not clearly detected constitutively active CB1 receptors in cerebellar 
membranes, as the actions of SR141716A were shown to either be non-CB1 receptor-specific or 
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the constitutive activity in these membranes was not able to be detected by the constraints of the 
[35S]GTPγS binding assay (Sim-Selley et al. 2001). 
A number of proteins have been found to interact with GPCRs, often mediating some level of 
control over G-protein signaling, including basal activity.  β-arrestin and G-protein receptor 
associated sorting protein (GASP1) are known to bind to numerous GPCRs, including CB1, and 
regulate internalization, downregulation and ultimately degradation (Martini et al. 2010, Bohn, 
2009; Smith et al. 2010).   The site of these protein-protein interactions is almost exclusively at 
the C-terminus, which is often not well conserved across GPCRs and subject to post-translational 
modifications.  High sequence variability among the C-terminal tails of GPCRs allows for 
selectivity.  It has been shown in metabotropic glutamate receptors that selective regulatory 
proteins competitively bind at the C-terminus and modulate constitutive activity (Ango et al. 
2001).  Thus, it is possible that many GPCRs known to exhibit constitutive activity might also 
interact with a regulatory protein that manages their tonic activity.  
 
Figure 4. Receptor conformation state depends on stability induced by its environment.  
Previous receptor theories described two states: a closed, inactive receptor in the absence of 
ligand or presence of an antagonist, and an open active receptor when agonist is present.  Inverse 
agonists are now thought to stabilize the receptor in an inactive conformation better than 
antagonists, and agonists are no longer thought to be required for the receptor to be in an activate 
state.  However, agonists stabilize the active state. 
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1.6 Cannabinoid Receptor Interacting Protein 1a. 
As discussed above, CB1 receptors exhibit significant constitutive activity (Pan et al. 1998), 
and in 2001, Nie and Lewis found that truncation of the distal C-terminal tail led to increases in 
tonic inhibition of calcium channel currents. This evidence led to the speculation and search for a 
protein capable of regulating CB1 receptor constitutive activity that possibly binds to the distal 
portion of the C-terminus.  Yeast two-hybrid screening of a human cDNA library using the last 
55 amino acids (aa 418 – 472) of the CB1 C-terminal tail as bait revealed the successful retrieval 
of a new protein sequence (Niehaus et al. 2007).  The gene encoding this protein sequence was 
found on human chromosome 2, and contains two alternative splice sites that produce the 
Cannabinoid Receptor Interacting Protein 1a (CRIP1a) and the Cannabinoid Receptor Interacting 
Protein 1b (CRIP1b), respectively.  CRIP1a is comprised of 164 amino acids encoded by exons 1, 
2 and 3a, while CRIP1b is slightly smaller at 128 amino acids encoded from exons 1, 2 and 3b.  
In mice, the gene for CRIP1a, Cnrip1, is on chromosome 11 and does not appear to contain exon 
3b.  CRIP1b has not been well studied, and its function is largely unknown, in part because it is 
thought to be only expressed in primates.  CRIP1a on the other hand, is expressed throughout 
vertebrates and has been shown to have a primary role in inhibiting CB1 receptor constitutive 
activity by binding to the last 9 amino acids of its C-terminus (Niehaus et al. 2007).  One study 
also shows a possible role in mediating CB1 antagonist-induced neuroprotection from glutamate 
excitotoxicity (Stauffer et al. 2011).  To date, CRIP1a has not been shown to interact with other 
GPCRs, including CB2 receptors.  Homology searches in silico showed that the 9 amino acid 
binding sequence required for association of CRIP1a with the CB1 receptor was not present on the 
C-terminus of any other GPCR.  CRIP1a does however contain a PSD-95, Disc large protein and 
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ZO-1 (PDZ) ligand domain on its own C-terminus, signifying that it could interact with other, 
PDZ domain-containing proteins, but not in the same manner that it interacts with CB1 receptors.   
CB1 receptor expression is unaffected by CRIP1a as indicated by [3H]SR141716A saturation 
binding in stably co-transfected HEK-293 cells (Niehaus et al.2007).  Yet, inconsistent results 
have been found regarding agonist-stimulated CB1 receptor activation.  Niehaus et al. (2007) 
also showed that CB1-microinjected SCG neurons with and without co-expression of CRIP1a did 
not display differences in Ca2+ current inhibition after WIN 55,212-2 activation of CB1 receptors.  
Our laboratory, however, has shown that CRIP1a inhibited agonist stimulated G-protein activity 
in N18TG2 (Figure 5) and CB1-HEK-293 cells (not shown) stably over-expressing CRIP1a and 
furthermore, attenuated the inverse agonist effects of rimonabant (unpublished data, Figure 5).  
Potential changes in CB1 receptor levels were again measured by [3H]SR141716A saturation 
binding, however, no differences in Bmax or KD values were found in either cell line with and 
without stable ove-rexpression of CRIP1a. 
CRIP1a and CB1 receptors have been shown to co-localize in superior cervical ganglion 
neruons (SCG) microinjected with cDNA encoding CRIP1a and human influenza hemagglutinin 
(HA) tagged CB1 receptors (Niehaus et al. 2007).  The major finding in that study suggested that 
CB1 receptors and CRIP1a do indeed interact, and more importantly, the site of interaction 
occurred at the plasma membrane, where GPCRs are known to exert their signaling effects.  Co-
localization has also been reported between the two in cone photoreceptor cells (Hu et al. 2010).  
One interesting finding from that study showed CRIP1a was limited to presynaptic terminals, but 
that it reliably aligned with postsynaptic DAGLα in a one to one ratio.  CRIP1a was also found to 
co-localize with CB1 receptors on the outer plexiform layer within the synapse, thereby 
reinforcing a likely role of CRIP1a in CB1-mediated signaling.   
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CRIP1a has also been investigated within the human brain for its potential association with 
epilepsy (Ludányi et al. 2008).  Hippocampal tissue was obtained post-mortem from individuals 
who suffered from therapy-resistant temporal lobe epilepsy, as well as from those with no known 
neurological disorders to serve as controls.  RNA was extracted from control subjects’ 
hippocampal tissue and epileptic subjects’ sclerotic and non-sclerotic hippocampal tissue.  CB1, 
CRIP1a and CRIP1b mRNA levels were then quantified relative to two housekeeping genes, β-
actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), using qPCR.  CB1 and CRIP1a 
mRNA levels were significantly reduced in sclerotic hippocampal tissue of epileptic patients 
compared to controls, while no changes were observed in CRIP1b.  This study was the first to 
show CRIP1a mRNA levels were altered in tandem with CB1 receptor mRNA in response to a 
neurological disease.   
Another study also focused on CB1 receptors and CRIP1a within the hippocampus in a rat 
model of epilepsy by inducing seizures with the excitotoxin, kainic acid (KA).  This time, results 
indicated that after KA administration, CB1 and CRIP1a mRNA expression was increased 
compared to controls. Though these results differ from the human study described above, the KA 
model in rats and therapy-resistant temporal lobe epilepsy in humans do not exhibit the same 
pathology, thus potentially eliciting different alterations to the endocannabinoid system.  The 
parallel expression patterns between CRIP1a and CB1 receptors are consistent with the previous 
study, however.  
CRIP1a has additionally been linked to glutamate excitotoxicity by engaging in a novel 
“switching” mechanism as shown by Stauffer et al. (2011).  In this study, primary cortical 
neurons with and without over-expression of CRIP1a were treated with the cannabinoid agonist, 
WIN, or the antagonist, SR141716A, and challenged with excess glutamate.  Over-expression of 
	  	   17 
CRIP1a was found to block the cannabinoid receptor-mediated neuroprotective role of WIN.  
However, when these neurons were treated with SR141716A, the neuroprotective mechanisms 
were restored.  Furthermore, those neurons over-expressing CRIP1a yielded a similar level of 
protection against excitotoxicity (roughly 30% less cell death) when compared to neurons treated 
with WIN but not over-expressing CRIP1a.  These results suggest that CRIP1a might have 
additional capabilities in modulating CB1 signaling, beyond that of negative regulation.   
New evidence has begun to illustrate potential roles of CRIP1a in other receptor systems.  A 
viral knockdown approach was used in rat dorsal striatum to show that when CB1 receptors are 
significantly reduced, dopamine D2 (D2) receptors follow suit, thus suggesting cooperative 
regulation of the expression of these receptors within the striatum.  CRIP1a expression was 
subsequently found to increase as a result, suggesting a possible role in modulating D2 receptors 
or acting as a modulator of the D2:CB1 receptor interaction (Blume et al. 2013).  In addition, this 
study also examined virally mediated over-expression of CRIP1a within the striatum. 
Interestingly, a trend was observed in which WIN-stimulated G-protein activation was reduced, 
which agrees with our own laboratory’s data in cell lines over-expressing CRIP1a, which showed 
significant reduction in WIN-stimulated G-protein activation (see Figure 5).  Together, these 
results continue to suggest that CRIP1a negatively regulates CB1 receptors.  
Previous studies have primarily involved over-expression of CRIP1a, which can be laden with 
pitfalls resulting from over-expressing or ectopically introducing a protein into a system.  A 
critical complementary strategy is to use “loss-of-function” approaches to reduce or eliminate 
gene expression in tissues where it is normally expressed.  We chose the gene knockout approach 
in mice because it provides a complete loss of gene expression and allows us to study the 
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consequences of this deletion both in vitro and in vivo.  Thus, this approach can provide 
information about the function of CRIP1a in the intact animal.   
This thesis outlines the first studies and findings of CRIP1a function in the whole animal.  
Both behavioral assessments and in vitro studies were performed on the first CRIP1a knockout 
(KO) mouse line, which was developed at VCU by our laboratory in collaboration with Dr. 
Ching-Kang Chen’s laboratory in the Department of Biochemistry and Molecular Biology.  My 
hypothesis is two fold: that CRIP1a KO mice might exhibit cannabimimetic phenotypes due to 
increased CB1 receptor activity (either constitutive or endocannabinoid-mediated) and/or that 
these mice will display an enhanced response to cannabinoid agonists compared to littermate 
wild-type (WT) mice.  Behavior will be assessed first in a naïve state with particular attention to 
responses that are known to be mediated by CB1 cannabinoid receptors.  These responses include 
measures of antinociception, evaluated by the warm water tail withdrawal assay and the hot plate 
assay, measures of locomotor activity and motor coordination, and finally, measures of anxiety-
like behaviors.  Mice will subsequently be administered cannabinoid agonists to determine 
whether CRIP1a KO mice exhibit altered sensitivity to agonist when this regulatory protein is 
absent.  The brains of CRIP1a WT and KO mice will be dissected into specific regions and 
investigated for differences in CB1 receptor levels, ligand affinities and basal and agonist-
stimulated G-protein activity.  CRIP1a expression levels will further be assessed in CB1 receptor 
WT and KO mice treated chronically with either vehicle or THC.  As a whole, I expect to unveil 
specific novel findings related to CRIP1a function in the CNS in vitro and for the first time, in 
vivo, by investigating behavioral and physiological responses in the whole animal.  These studies 
will provide a greater understanding of the potential roles of CRIP1a in mediating or modulating 
CB1 receptor signaling and function.  
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Figure 5. Agonist-stimulated [35S]GTPγS binding in N18TG2 cell lines with and without 
overexpression of CRIP1a.  WIN55,212-2 (WIN) and methanandamide (MAEA) stimulation 
above basal, and rimonabant (RIM) suppression below basal levels were significantly attenuated 
by CRIP1a overexpression. Data are expressed as mean ± SEM (n =4 experiments performed on 
separate days).  
	  	   20 
 
Chapter 2. Materials and Methods  
 
2.1 Materials.    
[3H]CP55,940 (88.3 Ci/mmol) and CP55,940 (-) was obtained from the National Institute on 
Drug Abuse drug supply program (NIDA, Rockville, MD).  [35S]GTPγS (1250 Ci/mmol) was 
purchased from Perkin Elmer Life Sciences (Boston, MA). Econo-Safe scintillation fluid was 
purchased from Research Products International Corporation (Mount Prospect, IL).  Bovine 
serum albumin (BSA), GTPγS, GDP and WIN 55,212-2 (dissolved in ethanol) were purchased 
from Sigma-Aldrich Chemical Company (St. Louis, MO).  Whatman GF/B filters were 
purchased from VWR (Bridgeport, NJ). Methanandamide (ethanol) was purchased from Cayman 
Chemical (Ann Arbor, MI).  Noladin Ether (ethanol), CP55,940 (ethanol) and SR-141716A 
(ethanol) were provided by the Drug Supply Program of the National Institute on Drug Abuse 
(NIDA, Rockville, MD).  Protease Inhibitor Cocktail was purchased from Promega Co. 
(Madison, WI).  CRIP1a antisera 077.4 was provided by Dr. Maurice Elphick (Queen Mary 
University of London). α-Tubulin antisera DM1A was purchased from Abcam (Cambridge, 
MA).  Licor Odyssey infrared dye-conjugated secondary antibodies were purchased from Li-Cor 
Biosciences (Lincoln, NE).  The High Capacity cDNA Reverse Transcription kit was purchased 
from Applied Biosystems (Grand Island, NY).  The QuantiFast SYBR Green RT-PCR Kit was 
purchased from Qiagen (Germantown, MD). MyTaq™ Red PCR Master Mix was purchased 
from Bioline (Taunton, MA).  Trizol® was purchased from Invitrogen Life Technologies 
(Carlsbad, CA).  All other chemicals, including salts, buffers, chelating agents, detergents and 
acrylamide were reagent grade and purchased from Sigma-Aldrich Chemical Company (St. 
Louis, MO) or Fisher Scientific (Waltham, MA).  
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2.2 Generation of the Cnrip1 Knockout Mouse Line.   
A targeting vector for the Cnrip1 locus was developed that replaces all of exon 1 and 2, 
including 214 base pairs upstream of exon 1 and 590 base pairs downstream of exon 2 with a 
neomycin (NEO) cassette (Figure 6).  The homology arms were amplified by PCR using the 
BAC clone RP23-348N2 (CHORI BACPAC Resources, Oakland, CA) as template. The left 
homology arm was amplified by PCR primers CNRIP1-LAXhoF: 
ACCGctcgagGATCCACAGGAATTGTGCT and CNRIP1-LABgl2R: 
CTAagatctAAACGGGGTAGGAAACTGCT yielding a 1.6kb product. The right homology arm 
was amplified by PCR primers CNRIP1-RANotF: 
ATAAGAATgcggccgcCATGGATGCAGAGCCTATT and CNRIP-RANotR: 
ATAAGAATgcggccgcTTGGCATCATCAGAACCAAA yielding a 4.0kb product. The left 
homology arm PCR product and DNDF-7 vector was digested with XhoI and BglII and ligated. 
Afterwards, the right homology arm and the DNDF-7-LA (which contains the left homology 
arm) was digested with NotI and ligated to form the final targeting vector construct. The 
targeting vector was linearized with BsiWI and purified by phenol/chloroform extraction prior to 
electroporation.  By replacing some of the upstream sequence, the transcriptional start site and a 
portion of the promoter are no longer present after homologous recombination, therefore 
essentially eliminating the possibility that exon 3, which remains intact, could be transcribed into 
mRNA.  Two diphtheria toxin A (DTA) cassettes were included in the targeting vector to serve 
as negative selection controls.  The targeting vector was created by our collaborators, Drs. Hoon 
Shim and Ching-Kang (Jason) Chen, in the Department of Biochemistry and Molecular Biology, 
VCU School of Medicine. 
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The targeting vector was sent to inGenious Targeting Laboratory, Inc. (Ronkonkoma, NY) 
for the development of chimeric mice on a 50% C57Bl6 and 50% 129sv mixed-strain 
background.  The chimeric mice were sent to VCU and bred to produce heterozygous offspring, 
which were screened for germline transmission by standard PCR methods using specific primers 
(Figure 7).  The mice carrying a copy of the NEO allele were then bred to each other to form the 
founder population for the CRIP1a mouse line.  Heterozygous breeding pairs were maintained 
from that point onward. 
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Figure 6. Maps of wild-type Cnrip1 locus and the targeting vector. The Cnrip1 coding sequence 
is represented in black and non-coding sequences in exon1 and exon3 are represented in gray. 
Arrows represent PCR primer locations.  The targeting vector replaces all of exon1 and exon2, 
along with 214 bp upstream of exon1 and 590 bp downstream of exon2 with a NEO cassette. The 
targeting vector contains the NEO cassette for positive selection and 2 DTA cassettes for 
negative selection.  
 
 
 
 
Figure 7. Germline transmission of Cnrip1 KO allele achieved in 3 mice.  Lanes 1 and 6 
represent mice that are wild type for the Cnrip1 locus.  Lanes 2, 3 and 4 represent mice carrying 
the NEO allele, indicating these mice are the first heterozygous germline carriers of the Cnrip1 
locus.  Lane 7 is a blank (negative) control, followed by a ladder for confirmation of product 
fragment size.   
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2.3 PCR Genotyping of Cnrip1 Mutant Mice.  The resulting litters were weaned at 21 days of 
age and a small tissue sample from each weanling was collected for genotyping.  DNA was 
extracted and isolated via the HotSHOT method (Truett et al. 2000). The primer pair for the wild 
type (WT) allele is 3’ GACCACTCACAAATGCCA-GA 5’ (forward) and 3’ 
GCACTCTAGGTTAATAGGCTCTGC 5’ (reverse).  The primer pair for the knockout (KO) 
allele, which probes for the NEO cassette, is 3’ GAGACGT-GCTACTTCCATTTGTC 5’ 
(forward) and 3’ GCACTCTAGGTTAATAGGCTCTGC 5’ (reverse).  The reverse primer 
sequence is the same for both alleles.  All experiments were performed using mice maintained on 
the mixed background described earlier.    
 
2.4 Measuring Body Weight and Core Body Temperature. 
Subjects. Subjects included littermate male and female CRIP1a WT, heterozygous (HET) and 
KO maintained on a mixed (50/50) 129sv/C57Bl6/J background. The mice were housed 
according to sex in groups of up to 5 per cage and maintained in a temperature-controlled 
environment (20-22ºC) in an American Association for the Accreditation of Laboratory 
Approved Animal Care-approved vivarium.  Food and water were available ad libitum. The mice 
were kept in a 12-hour light/dark cycle with lights on at 06:00.   
Body Weight.  All mice were weighed weekly from weaning (3 weeks) until 12 weeks of age 
using a WeighMax™ gram scale.  Mice were again assessed four weeks later, at 16 weeks of 
age.   
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Core Body Temperature. Adult mice (12-16 weeks) were assessed for core body temperature, 
measured using a 2.0 cm rectal thermocouple probe. Temperatures were obtained from a 
telethermometer.  Mice were returned to their home cages after testing was completed. 
 
Data Analysis. Body weights were analyzed via two-way ANOVA followed by Bonferroni post 
hoc test.  Core body temperature was analyzed by student’s t-test.  Significance was reached 
when p < 0.05 for both measures.  
 
2.5 Behavioral Phenotyping: Baseline Tests of Nociception, Spontaneous Motor Activity, 
Motor Coordination, and Anxiety in Drug-Naïve Mice.   
  
Subjects. Subjects included littermate male and female CRIP1a WT and KO maintained on a 
mixed (50/50) 129sv/C57Bl6/J background.  The mice (20-30g) were housed as described above 
(Section 2.4).   All experiments were performed during the hours of the light cycle.   
 
Nociception.  Thermal nociception was evaluated using two assays.  The first was a warm water 
tail withdrawal procedure that measured the time in seconds for a mouse to remove its tail from a 
warm water bath set to 48º, 52º or 56ºC.  Mice were lightly restrained using a padded body bag 
covering all but the tail.  Once settled, the distal portion of the tail was inserted into a warm 
water bath and a timer immediately started.  The timer was stopped when the mouse fully 
removed its tail from the water, typically observed as a flicking motion.  A cut-off time of 10 
seconds was used to avoid any possible tissue damage to the tail.  Mice were placed back into 
their home cage until further testing was performed at higher temperatures.   
The second test used a hot plate to measure the amount of time in seconds for a mouse to lift, 
lick or shake one of its hind paws from the warm surface set to 52º or 56ºC.  Mice were gently 
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placed onto the hot plate and barricaded by a clear acrylic cylinder measuring 7.5 cm in 
diameter.  A mirrored back panel increased visibility appreciably, providing nearly a 360º view 
of the mouse.  Once all four paws were planted on the plate surface, the timer was started.  A 20 
second cut-off time was applied to avoid soft-tissue damage to the paws.  The trial ended when 
the mouse elicited any of the lifting, licking or appendage shaking behaviors indicating a 
response to the nociceptive stimulus.  The cylinder barricade was removed and the mouse was 
lifted from the plate and placed back into its home cage. 
 
Locomotor activity.  Spontaneous motor activity was assessed using ANY-maze™ video 
tracking software (Stoelting Co., Wood Dale, IL) in tandem with Fire-i™ digital cameras 
(Unibrain, San Ramon, CA) mounted from the ceiling of sound-attenuating cabinets.  A 
rectangular barrier made of clear plastic was set on a white tray (30 cm L x 15 cm W), forming 
the open-field test parameters.  Mice were evaluated individually and were placed in the center 
of the tray to begin the test.  The cameras began recording immediately after the cabinet door 
was latched closed and movements of each mouse were tracked for 30 minutes.  Any motion, 
including forward movement, turns, immobility and bouts of freezing were documented within 
the 30-minute time period.  Mice were tested in the absence of drug and had no previous 
exposure to this particular chamber set-up due to reports of environmental habituation (File, 
2001).         
 
Motor coordination.  Motor coordination was evaluated using an IITC RotaRod apparatus 
(IITC Life Science, Inc., Woodland Hills, CA) fitted with 1¼ inch diameter drums.  Mice were 
trained at 10 rpm two separate times for up to 120 seconds each.  Any animals that clung to the 
drum and spun with it rather than walking on top were considered to have made a “passive 
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rotation”, which ended the training session as if they had fallen.  Any mouse that jumped from 
the drum was scored by the distance and rpm at which it jumped.  After two training sessions, 
mice were then tested at 16 rpm for a maximum of 120 seconds.  Again, passive rotations and 
jumps ended the test, with their performance based on the last rpm and distance recorded prior to 
jumping or rotating.  Data were collected for both training and testing trials, however only the 
scores for maximum rpm and distance at 16 rpm were analyzed.   
 
Anxiety-like behavior.  Anxiety-like behaviors were assessed using two assays: the light:dark 
box and marble burying.  All mice examined were naïve to the assay environments and had not 
been pretreated with any drug.  The light:dark box chamber (Stoelting Co., Wood Dale, IL) was 
placed inside a sound-attenuating cabinet complete with ceiling-mounted Fire-i™ digital 
cameras.  The video tracking software, ANY-maze™, was used to record the animal’s 
movements.  The light compartment measured 20.5 cm x 40 cm and was surrounded by clear 
plastic panels and an open ceiling.  The dark compartment was smaller, measuring 10 cm x 40 
cm, and was enclosed by black panels on the top and sides.  Infrared camera technology was 
used to view the mice while in the dark compartment.  A small throughway measuring 7 cm x 7 
cm allowed the mice to freely move between chambers.  Mice were initially placed in the bottom 
right-hand corner of the light compartment, lit by a 60W bulb above.  The cabinet door was 
latched closed and the five-minute tracking period was initiated, recording the movements within 
and between the light and dark chambers.  After five minutes, the mice were returned to their 
home cage.  Due to habituation, the same mouse was never tested twice.   
To evaluate the mice in the marble burying assay, a cage measuring 12.5 x 8 inches (100 in2) 
was filled with minced wood chips reaching a depth of 3 inches.  Bedding was not compacted to 
encourage mobility of marbles.  Twenty clear marbles (14 mm circumference) were placed in a 4 
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x 5 pattern, evenly spaced throughout.  The mice were each given twenty minutes to explore the 
surroundings and the opportunity to bury marbles.  A clear plastic panel was placed on top to 
prevent mice from jumping or climbing out of the cage.  After twenty minutes had elapsed, mice 
were carefully removed and placed back in their home cage.  Marbles were then assessed for 
buried status.  Any marble whose surface was more than 50% covered by bedding was 
considered buried.  The number of marbles remaining unburied was counted and then subtracted 
from 20 to obtain the actual number of marbles buried.  
 
2.6 Data analysis: Baseline Tests of Nociception, Spontaneous Motor Activity, Motor 
Coordination, and Anxiety in Drug-Naïve Mice.  
 
Nociception.  Latencies for warm-water tail withdrawal and hot plate were analyzed by student’s 
two-tailed t-test with significance reached at p < 0.05.  
 
Locomotor Activity.  When collapsed by test segment, time mobile, time immobile and time 
freezing were analyzed using student’s two-tailed t-test with significance reached when p < 0.05.  
When analyzed separately as three separate test segments, two-way ANOVA followed by 
Bonferroni post hoc test was used.  Significance was reached when p < 0.05.  
 
Motor Coordination.  RotaRod performance was analyzed by student’s two-tailed t-test for 
both latency to fall and distance travelled.  Significance was reached when p < 0.05.  
 
Anxiety-like behavior.   Light:dark box and marble burying scores were analyzed using 
student’s two-tailed t-test, with significance reached when p < 0.05.   
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2.7 Behavioral Phenotyping: Tetrad Assessment of Nociception, Catalepsy, Body 
Temperature and Motor Coordination After CP55,940 Administration.  
 
Subjects.  Subjects were adult littermate CRIP1a WT, HET and KO male mice, 25-35g in body 
weight. Mice were housed and fed as described in Section 2.4. 
 
Modified “Tetrad” Test with Cumulative Drug Dosing.  Mice were evaluated for a series of 
behaviors and physiological responses known to occur with cannabinoid agonists, compiled into 
a modified “tetrad” assessment.  Traditionally, spontaneous locomotor activity is included in this 
set of experiments (Little et al. 1998), however, due to our implementation of a cumulative 
dosing protocol (see below) and evidence suggesting habituation of mice after repeated 
exposures to the locomotor evaluation chambers, we chose to examine motor coordination using 
an accelerating RotaRod protocol instead (for review, see Deacon, 2013).  The remaining three 
portions of the tetrad assay were still examined, which include rectal temperature, catalepsy and 
warm water tail withdrawal.  Antinociception was also evaluated in the hot plate assay. 
Mice were acclimated to shoebox cages where the average ambient temperature was 24 ± 
2°C and 35% humidity for at least 1 hour prior to testing.  CP55,940 was dissolved in dimethyl 
sulfoxide (DMSO) and added to emulphor and saline for a final vehicle ratio of 1:1:18; 
DMSO:emulphor:saline.  CP55,940 was administered to mice using a cumulative, within-session 
dosing protocol.  The CP55,940 concentrations were as follows: 0.001 mg/ml (0.01 mg/kg), 
0.003 mg/ml (0.03 mg/kg), 0.007 mg/ml, (0.07 mg/kg), 0.02 mg/ml (0.2 mg/kg), and 0.07 mg/ml 
(0.7 mg/kg), which result in cumulative doses of 0.01, 0.03, 0.1, 0.3, and 1 mg/kg, respectively.  
Baseline values for catalepsy, tail withdrawal latency, hot plate latency, rotarod performance and 
rectal temperature were assessed for each mouse in that order prior to any injections (least 
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invasive to most invasive).  Intraperitoneal (i.p.) injections were administered in a volume of 1 
ml/100 g bodyweight 30 minutes prior to testing the effects of each dose, with 10 minutes 
lapsing between the end of the previous test session and the next round of injections.  
To evaluate catalepsy, the front paws of each mouse were placed on a bar measuring 0.75 cm 
in diameter and set to a height of 4.5 cm from the bench surface.  If the mouse remained in place, 
a timer was started.  Any movement(s) beyond normal respiration stopped the timer.  Up to 3 
attempts could be made to reposition the mouse if it moved at any point within a 60 second time 
period.  All periods of immobility were totaled for the catalepsy score, with 60 seconds being the 
maximum.  Nociception was assessed using the warm water tail withdrawal assay and the hot 
plate assay.  Both tests were performed at 52ºC as previously described (see section 2.5).   Motor 
coordination was assessed at each time point by placing the mice on a stationary RotaRod drum, 
facing outward.  The drum was set to begin moving at 6 rpm and accelerate to a maximum of 25 
rpm over a span of 60 seconds.  The rpm and time in seconds at which the mouse fell off the 
drum, or completed a passive rotation (spun with the drum), was scored as the maximum 
performance for that trial.  Core body temperature was measured using a 2.0 cm rectal 
thermocouple probe, and temperatures were obtained from a telethermometer.  Mice were 
returned to their home cages after testing was completed.  
 
Data Analysis.  CP55,940 dose-effect curves were analyzed by two-way ANOVA with p < 0.05 
determining significance.  Data for catalepsy and both measures of nociception were transformed 
to %MPE and analyzed by two-way ANOVA, with p < 0.05 determining significance.  %MPE 
was calculated using the following equation: [(test latency – control latency) ÷ (max latency – 
control latency)] x 100.  Maximum latencies were determined by specific cut-off times 
associated with each test.  The cut-off for catalepsy was 60 seconds, the cut-off for hot plate was 
	  	   31 
20 seconds and the cut-off for warm water tail withdrawal was 10 seconds.  Any subject that 
reached the cut-off time was immediately removed from the test apparatus and assigned the 
maximum time score allowed.  
 
2.8 Dissections.  Brains were removed from the skull and forebrain regions of interest were 
dissected.  The hippocampus and amygdala were then dissected from the remaining brain for the 
current studies.  The cortex was removed from the superior surface of the brain to expose the 
hippocampus.  Cuts were made at the anterior and posterior aspects of the hippocampus to 
produce a thick coronal section.  The piriform cortex was removed, and the amygdala was 
dissected from the ventral lateral aspect of the section using the optic tract and bifurcation of the 
corpus callosum as landmarks.  This dissection included most amygdalar subnuclei, except those 
at the most posterior extent of the complex. The hippocampus was then removed from the 
remaining section using the corpus callosum as an interior border.  This dissection included most 
of the hippocampal complex.  The whole cerebellum was collected by separating from the 
brainstem.  The spinal cord was collected by using the decapitation cut as the anterior border and 
making a second cut at the level of the hip bone as a posterior border.  The spinal cord was then 
extracted by inserting a ddH2O filled 40 ml syringe fitted with a 200 µl pipette tip into the spinal 
column at the posterior end and expelling under pressure.  This procedure expels the whole intact 
spinal cord, although the initial cervical portion of the spinal cord is likely lost during 
decapitation and the most posterior sacral segments might not be included.  The use of the 
decapitation point and hip bone as anterior and posterior landmarks, respectively, provides a 
consistent sample for analysis.  Tissue was immediately frozen on dry ice and stored at -80°C 
until use. 
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2.9 Membrane Preparation (for Binding Assays).   Mice were euthanized by rapid 
decapitation with a sharp guillotine.  Brain regions were dissected on ice as described in Methods 
2.8 and immediately frozen and stored at -80°C.  Once thawed, the tissue was homogenized in 50 
mM Tris-HCl, 3 mM MgCl2, 0.2 mM ethylene glycol tetraacetic acid (EGTA), 100 mM NaCl 
pH 7.4 (assay buffer) using a Polytron homogenizer for 10 seconds.  If homogenates were used 
in receptor saturation binding experiments, the assay buffer was comprised of the previous recipe 
minus 100 mM NaCl.  Homogenates were centrifuged at 50,000 x g at 4°C for 10 minutes and 
resuspended in assay buffer.  Membrane protein levels were assessed via the Bradford method, 
using 1 mg/ml BSA as the standard (Bradford, 1976). 
 
2.10 Whole Homogenate Preparation (for Immunoblotting).  Mice were euthanized as above 
and brain regions were dissected on ice as described in Methods 2.8, and immediately frozen and 
stored at -80°C.  Once thawed, the tissue was homogenized via sonication in cell lysis cocktail 
buffer (electrophoretic mobility shift assay  (EMSA) buffer (20 mM HEPES at pH 7.8, 0.4 M 
NaCl, 5 mM MgCl2, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 0.1 mM EGTA, 1% NP-
40, 20% glycerol) plus 1% protease inhibitor and 0.1% dithiothreitol (DTT).  Samples were 
centrifuged at 15,000 x g for 10 minutes at 4ºC.  The supernatant was saved and the pellet was 
discarded.  Protein concentrations were determined using the Bradford method, with 1 mg/ml 
BSA as the standard (Bradford, 1976).  
 
2.11 [3H]CP55,940 Binding.  Membranes (10-30 µg protein) were incubated for 90 minutes at 
30°C in assay buffer (with no NaCl) plus 0.5% (w/v) BSA containing ascending concentrations 
of [3H]CP55,940 ranging from 0.1 nM to 5 nM, with and without 5 µM unlabeled CP55,940 to 
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measure nonspecific and total binding values, respectively.  Total reaction volume was 0.5 ml.  
At the end of 90 minutes, the reaction was terminated by rapid vacuum filtration through GF/B 
glass fiber filters that were presoaked in cold Tris-HCl buffer (pH 7.4) containing 0.5% (w/v) 
BSA.  Bound radioactivity was determined using liquid scintillation spectrophotometry at 45% 
efficiency for [3H]. 
 
2.12 [35S]GTPγS Binding. Membranes (5-10 µg protein) were incubated for 15 minutes at 30ºC 
in the presence of 2 µl/ml adenosine deaminase (ADase) immediately prior to assay.  This step 
inactivates endogenous adenosine, which can be tightly bound to G-protein-coupled adenosine 
receptors thereby elevating basal [35S]GTPγS binding (Moore et al., 2000).  ADase pretreated 
membranes were then added to assay buffer containing various drugs, 30 µM GDP, 0.1% BSA 
and 0.1 nM [35S]GTPγS in a total volume equaling 0.5 ml, which was then incubated for 2 hours 
at 30ºC.  Basal [35S]GTPγS binding was evaluated in the absence of agonist and non-specific 
binding was measured using 10 µM unlabeled GTPγS.  The assay was terminated by rapid 
vacuum filtration through GF/B glass fiber filters.  Bound radioactivity was determined by liquid 
scintillation spectrophotometry at 95% efficiency for [35S].  
 
2.13 Immunoblotting.  Tissue homogenates of varying concentrations (25–100 µg) were added 
to sample buffer (1 M TRIS, 20% SDS, 1 M DTT, 60% w/v sucrose, bromophenol blue) and 
denatured by boiling for 5 minutes.  The protein samples were loaded onto a 15% 
polyacrylamide gel and separated via electrophoresis conducted at 120 volts for 90 minutes.  
Protein was then electrophoretically transferred to a nitrocellulose membrane at 70 volts for 1 
hour.  Blots were blocked using 5% (w/v) nonfat dry milk in 0.1 M TRIS-buffered saline (TBS) 
for 1 hour at room temperature. They were then incubated overnight at 4°C in blocking buffer 
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plus 0.1% Tween 20 containing primary antibody: anti-CRIP1a antisera 077.4 (rabbit) 1:1000, 
and a loading control, anti-αTubulin [DM1A] (mouse) 1:15,000.  Blots were rinsed 3 x10 
minutes in 0.1M TBS + 0.1% Tween 20 (TBST).  The blots were incubated at room temperature 
for 45 minutes with the secondary antibodies: Licor goat anti-rabbit 800 CW IR dye, 1:15,000 
and Licor goat anti-mouse 680 CW IR dye, 1:15,000.  Blots were rinsed 1x10 minutes in TBST, 
1x10 minutes in 0.1M TBS, and stored in phosphate-buffered saline (PBS) prior to visualization 
with the Licor Odyssey® System.  
 
2.14 RNA Extraction and Quantitative PCR.  Cerebellum homogenates were sonicated in 0.5 
ml Trizol®.  Chloroform was added and the samples were shaken before centrifugation at 12,000 
x g for 15 minutes at 4ºC.  The supernatant was removed and isopropanol (200 µl) was added 
before incubating the samples for 10 minutes at room temperature.  The samples were then 
subjected to centrifugation at 12,000 x g for 30 minutes at 4ºC.  The pellets were then washed 
with 70% ethanol, prepared using diethylpyrocarbonate (DEPC) water.  The samples were 
centrifuged again for 10 minutes at 7,500 x g.  The supernatant was discarded and the pellets 
allowed to air dry before adding 20 µl molecular biology grade water.  The pellets were heated 
for 5 minutes at 65ºC and then measured for total RNA concentration and quality, assessed 
according to RNA/DNA ratio, by ultraviolet spectrophotometry.  RNA (5 µg) was then 
converted into cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems Inc., Foster City, CA).  cDNA (10 ng) was then added to 0.2 ml wells containing a 
master mix from the 2x QuantiFast® SYBR® Green PCR kit and specific primers at a final 
concentration of 0.4 µM and water added to a final volume of 25 µl.  Additional wells with no 
cDNA added served as no template controls (NTC) for each primer set.  Samples were placed in 
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a BioRad real-time thermocycler programed to a 2-step cycling protocol, followed by a melt 
curve step at the end of the reaction.  Cycle threshold (Ct) values were initially normalized to 
ΔCt values by subtracting sample Ct values from β-actin Ct values.  Data were further converted 
to ΔΔCt values and final mRNA quantification was calculated using the following equation: 2^(-
ΔΔCt) x 100 = % mRNA expression. 
 
2.15 Chronic THC treatment of CB1 WT and KO mice.  CB1 WT and KO mice (male 
littermates, 20-24g) were injected with vehicle (1:1:18 ethanol:emulphor:saline) or 10 mg/kg 
THC twice daily for 13.5 days.  Mice were sacrificed 24 hours after the last injection.  Brains 
were extracted and dissected on ice.  The cerebellum, prefrontal cortex, and amygdala were 
homogenized in a cell lysis cocktail (as described in Section 2.10) and prepared for 
immunoblotting.  
 
2.16 Data Analysis.  Unless otherwise indicated, binding data are reported as mean values ± 
standard error of the mean (SEM) of at least four independent experiments that were each 
performed in either duplicate ([3H]CP55,940 binding) or triplicate ([35S]GTPγS binding).  Data 
were analyzed using Graph Pad Prism v5.0c software.  Bmax, KD, Emax and EC50 values were all 
determined by non-linear regression analysis.  The equation used to fit the data is as follows: y = 
(Bmax )(L)/(KD +L) where y equals the amount of [3H]CP55,940 or [35S]GTPγS bound at each 
ligand concentration, L.  Emax and EC50 were calculated after log transformation of 
concentration-effect curves, such that logL was substituted for L in the equation shown above.  
Bmax represents the amount of [3H]CP55,940 bound at saturating concentrations of receptor 
ligand, while Emax is equal to the % stimulation observed at maximally effective concentrations 
of receptor ligand in agonist-stimulated [35S]GTPγS binding.  KD and EC50 values represent the 
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concentrations of receptor ligand that produce half maximal binding of [3H]CP55,940 or 
modulation of [35S]GTPγS binding, respectively.  Basal binding was determined in the absence 
of ligand.  Net-stimulated [35S]GTPγS binding is defined as agonist-stimulated binding minus 
basal binding.  Percentage of stimulation is defined by the following equation: % stimulation = 
(net-stimulated binding/basal binding) x 100.  Concentration-effect curves were compared for 
statistical significance using two-way ANOVA, with ligand concentration and genotype as the 
main factors.  Curve-fit values, including Bmax, KD, Emax and EC50 values, were compared 
between genotypes using the two-tailed Student’s t-test. 
Integrated intensities were measured on all Western blots using the Odyssey Licor Software 
2.1 and analyzed either by the two-tailed Student’s t-test or two-way ANOVA followed by the 
Bonferroni post hoc test.   
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  Chapter 3. Results  
 
3.1 Confirmation of CRIP1a Knockout Mouse Line.   
 
Targeted NEO cassette replacement of Cnrip1 exons 1 and 2 successfully yielded a CRIP1a 
knockout mouse. The first CRIP1a knockout mouse was initially verified by PCR genotyping 
(Figure 8).  To confirm that CRIP1a protein was absent in mice with the Cnrip1 KO genotype, 
Western immunoblots were performed on cerebellar homogenates of WT and CRIP1a KO mice 
(Figure 9).  As expected, results showed clear expression of CRIP1a immunoreactivity in WT 
mice, as indicated by a prominent band at 18 kD, the predicted molecular mass of CRIP1a.  In 
contrast, no CRIP1a was detectable in the cerebellar preparations from KO mice, even at 100 µg 
of protein.   Similar results were seen in hippocampal homogenates from CRIP1a WT and KO 
mice, such that CRIP1a immunoreactivity was detected in WT but not KO mice (data not shown). 
To determine whether CRIP1a is present throughout the central nervous system (brain and 
spinal cord), immunoblots were also performed on whole spinal cord homogenates.  CRIP1a 
protein has been shown to be present in whole brain homogenates, as well as peripheral tissues 
such as heart and lung (Niehaus et al. 2007), but no published results have shown the presence of 
CRIP1a in the spinal cord to date. Results obtained were two-fold: there was a strong positive 
result showing expression of CRIP1a in the spinal cord of WT mice and a clear absence of the 
CRIP1a immunoreactivity in KO mice.  These results also further confirmed antibody specificity, 
as indicated by the absence of CRIP1a immunoreactivity in KO mice, as well as providing 
evidence for CNS knockout of CRIP1a protein in this mutant mouse line (Figure 10).   
The presence of two copies of the Cnrip1 KO allele and the absence of CRIP1a 
immunoreactivity in the brain and spinal cord suggests that CRIP1a protein is absent in the KO 
genotype due to a lack of transcription of functional CRIP1a mRNA.  To test this hypothesis, 
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quantitative PCR (qPCR) was performed.  Two different primer sets were developed to assess 
various regions of the Cnrip1 locus (Table 1).  Results from both primer sets indicated that in the 
cerebellum, the CRIP1a KO mouse is producing a maximum of 0.4% Cnrip1 mRNA compared to 
the CRIP1a WT control.  These results confirm the essential absence of CRIP1a mRNA in CRIP1a 
KO mouse brain. 
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Table 1. qPCR primer sequences for Cnrip1 and the housekeeping gene, β-Actin. 
Sequence Gene  Product Length 
3’ GCCCTGTTTTCTTCAAGGTG 5’ (F) Cnrip1 212 bp 3’ TGTGTCATAGATGCCGGTGT 5’ (R) 
3’ CTGACGGGGAGAGAGTTGTC 5’ (F) Cnrip1 Exon3 169 bp 3’ CAATGGTCTCGCTTGTGGTA 5’ (R) 
3’ TGTTACCAACTGGGACGA 5’ (F) 
β-Actin 619 bp 3’ GGGGTGTTGAAGGTCTCAAA 5’ (R) 
 
 
 
 
 
 
Figure 8. Heterozygous breeding pairs produce WT (2), HET (3) and KO offspring (1). The 
knockout allele fragment is 334 bp and the wild type allele fragment is 248 bp, as shown relative 
to a 1kb ladder (L).    
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Figure 9.  CRIP1a WT and KO cerebellar homogenates probed with CRIP1a antiserum.  Cnrip1 
KO mice do not express CRIP1a, as shown compared to WT mice and relative to the loading 
control, α-tubulin. 
 
 
 
 
 
Figure 10.  CRIP1a is present in the spinal cord.  CRIP1a WT and KO spinal cord homogenates 
(50 µg) probed with CRIP1a antiserum.  Cnrip1 KO mice do not express CRIP1a, as shown 
compared to WT mice and relative to the loading control, α-tubulin.    
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3.2 Loss of CRIP1a Does Not Affect Viability, Fertility, Weight Gain or Core Body 
Temperature. 
The initial (and arguably most important) result when creating a knockout mouse line is 
determining if removal of the gene proves lethal.  CRIP1a KO mice were born healthy along with 
WT and HET siblings in the first litter produced by HET x HET pairing.  No overt 
morphological differences were observed at any point in CRIP1a KO mice during postnatal 
development or adulthood.  At first, CRIP1a HET mice were overrepresented relative to both WT 
and KO mice, however over time, genotypic ratios approached the Mendelian expectation of 
1:2:1, WT:HET:KO, with our mouse line currently yielding a 1:2.2:1 ratio.  Interestingly, the KO 
genotype is preferentially observed in male mice, with the overall ratio of male to female KO 
mice equaling 2 to 1 in litters obtained so far. 
The endocannabinoid system is an important player in male and female reproduction and 
endocrine function.  Many studies have revealed a role of CB1 receptors and endocannabinoids 
in sertoli cell proliferation, spermatozoa motility and the acrosomal reaction, which is essential 
for proper fertilization of an oocyte (Maccarrone et al. 2003; Rossato et al. 2005; Rossi et al. 
2007).  Aberrant CB1 receptor signaling has been shown to negatively affect oviduct transport of 
an embryo, leading to ectopic pregnancies, as well as to impede the implantation event of a 
blastula into the uterus (Wang et al. 2004; Paria et al. 2001).  Furthermore, arachidonic acid, a 
major metabolite of the endocannabinoids, is a precursor to prostaglandins and ultimately 
progesterone synthesis, which each play an important role in the estrous cycle (Wlodawer et al. 
1976; Milvae and Hansel, 1983; Korzekwa et al. 2010).  Given the vast involvement that the 
endocannabinoid system has been shown to have in reproduction, it was important to determine 
if the loss of CRIP1a would affect male or female fertility.  To test this question, a KO x KO 
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breeding pair was established.  After producing healthy pups and typical-sized litters, no impacts 
on fertility were detected in CRIP1a KO mice.  
Body weight is known to be maintained in part by the endocannabinoid system, and can be 
affected by exogenous administration of both CB1 agonists and inverse agonists (Gomez et al.  
2002; Williams et al. 1998; Colombo et al. 1998).  As a new knockout line, it was important to 
establish any differences related to body weight and weight gain over time in CRIP1a KO mice 
compared to WT littermates, especially given the potential for increased CB1 receptor activity in 
relevant regions of the CNS and gastrointestinal system.  Male and female CRIP1a WT, HET and 
KO mice steadily gained weight from the age of 3 weeks until 12 weeks indicating normal 
healthy development (Figure 11).  Body weights were not different between genotypes after two-
way ANOVA (p > 0.05).  
Cannabinoid agonists often produce hypothermic effects (Crawley et al. 1993; Little et al. 
1988), therefore it was necessary to determine whether core body temperature was affected in 
CRIP1a KO mice.  Male and female CRIP1a WT and KO mice were assessed for core body 
temperature in a naïve state.  Average body temperatures were nearly identical between the two 
genotypes, and therefore not significantly different after student’s t-test (p > 0.05) (Figure 12).   
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Figure 11. CRIP1a WT, HET and KO mice do not differ in body weight.  Male and female mice 
were weighed weekly to measure growth and development. The top panel displays male weight 
gain while the bottom panel displays female weight gain.  Data represent mean weight ± SEM, n 
= minimum 13 mice per genotype per sex. Two-way ANOVA determined body weight was not 
different between genotypes (p > 0.05). 
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Figure 12. Body temperature is not different in CRIP1a KO compared to WT mice.  Data 
represent mean temperatures ± SEM (collapsed by sex, n = 8 per genotype).  Student’s two-tailed 
t-test revealed no differences between genotypes (p > 0.05).  
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3.3 CB1 Receptor Expression is Unaltered in the Cerebellum, Hippocampus, and Amygdala 
of CRIP1a KO Compared to WT Mice.   
Previous studies in our laboratory have shown that CB1 receptor levels do not change in 
multiple cell lines after stable transfection/over-expression of CRIP1a, so we predict that genetic 
deletion of CRIP1a will not alter CB1 receptor expression levels in the CNS.  Nonetheless, 
because the global, lifelong absence of CRIP1a could produce adaptive changes in CB1 receptor 
expression, it was important to determine CB1 receptor levels in relevant CNS regions.  
Therefore, [3H]CP55,940 saturation binding analysis was conducted in three brain regions 
known to express CB1 receptors and CRIP1a, the cerebellum, hippocampus and amygdala.   
Results indicated there was no difference in CB1 receptor levels between genotypes in these 
regions, as indicated by ligand Bmax, values in CRIP1a KO mice compared to WT littermate 
controls (Table 2).   In addition, ligand KD values were also unaffected by loss of CRIP1a, as 
there were no significant differences between genotypes for any of the regions examined.  Data 
were analyzed using the two-tailed t-test with significance reached at p < 0.05.  
 
Table 2.  Bmax and KD Values from [3H]CP55,940 Saturation Binding Analysis in 
Cerebellum, Hippocampus and Amygdala of CRIP1a WT and KO mice.  
 
 
Bmax  (fmol/mg) KD (nM) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
Cerebellum 242 ± 45 262 ± 20 0.76 ± 0.09 0.64 ± 0.17 
Hippocampus  217 ± 27 281 ± 26 0.53 ± 0.06 0.68 ± 0.11 
Amygdala 206 ± 26 206 ± 22 0.73 ± 0.18 0.71 ± 0.17 
 
Saturation analysis of [3H]CP55,940 binding in CRIP1a WT and KO cerebellum, hippocampus 
and amygdala (data collapsed by sex, n = 8 per genotype). Data are mean values ± SEM.  No 
significant differences in Bmax or KD values were reached between genotypes (two-tailed t-test, p 
> 0.05).  
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3.4 Agonist-Stimulated [35S]GTPγS Binding Reveals No Differences in CB1 Receptor-
Mediated G-Protein Activity in the Cerebellum, Hippocampus and Spinal Cord of CRIP1a 
KO Compared to WT Mice.   
CRIP1a is known to bind to the C-terminus of CB1 receptors and inhibit their constitutive 
activity (see Introduction 1.6).  Previously, our laboratory demonstrated that CRIP1a could also 
inhibit agonist-stimulated G-protein activity when stably over-expressed in CB1 receptor-
expressing cell lines, which differs from published reports that showed no effect on agonist-
induced Ca2+ inhibition in co-transfected SCG neurons (Niehaus et al. 2007).  Without CRIP1a 
present, I hypothesized that CB1 receptors in the CNS would be more constitutively active and 
possibly exhibit increases in agonist-stimulated G-protein activity.  The first region evaluated 
was the cerebellum, due to its dense CB1 receptor expression as well as data suggesting 
widespread co-localization of CRIP1a and CB1 receptors on granule cell terminals in the 
molecular layer of the cerebellum (K. Sayers and D.E. Selley, unpublished results).  
Additionally, CB1 receptors within the cerebellum are thought to mediate in vivo effects such as 
reduced motor coordination after application of exogenous cannabinoids and contribute to 
reduced excitatory synaptic transmission onto Purkinje cells (DeSanty and Dar, 2001; Lévénès et 
al. 1998).  To determine the level of G-protein activation in CRIP1a WT and KO mice, agonist-
stimulated [35S]GTPγS binding was performed using the synthetic cannabinoid ligand CP55,940 
and the putative endocannabinoid noladin ether (NE) as agonists (Figure 13).  All [35S]GTPγS 
binding studies were performed by Aaron Tomarchio, a Laboratory Research Specialist in the 
laboratory of our collaborator, Dr. Laura Sim-Selley.  Two-way ANOVA analysis of the 
concentration effect curves revealed a significant main effect of genotype (p < 0.05) with 
CP55,940 and a trend towards significance with NE (p = 0.0889), such that CB1 receptor-
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stimulated [35S]GTPγS binding was slightly lower in CRIP1a KO compared to WT mice.  
However, no significant differences in Emax or EC50 values between genotypes were found with 
either agonist (Table 3a), whereby data were analyzed using the two-tailed t-test with 
significance reached at p < 0.05.  Basal G-protein activity was unaffected by the absence of 
CRIP1a (Table 3b).  A single concentration (10 nM) of the CB1 inverse agonist, SR141716A, 
which was previously found to produce maximal inhibition of basal [35S]GTPγS binding in CB1 
receptor-expressing cell lines, was also tested to detect any potential genotype differences in 
constitutive activity of the CB1 receptors in the cerebellum.  Previous data showed that over-
expression of CRIP1a in stably transfected cell lines attenuated inverse agonist activity, however 
no difference was seen in the effects of 10 nM SR141716A in CRIP1a KO mice compared to WT 
littermate controls (Table 3b).   However, it should be noted that only modest effects on 
[35S]GTPγS binding were seen with SR147116A in the cerebellum (11-17% inhibition). 
 Given that no enhancement of CB1 receptor-mediated G-protein activity was found in the 
cerebellum of CRIP1a KO mice, we next examined the hippocampus, another region dense in 
CB1 receptor expression and which is thought to be involved in the short-term memory 
impairments elicited by cannabinoids (Hampson et al. 2000).  We also found that CRIP1a 
immunoreactivity was detected in the hippocampus of WT but not CRIP1a KO mice.  Moreover, 
unpublished data from a collaboration between our laboratory and Dr. Alex Straiker (University 
of Indiana) found that transfection of CRIP1a into autaptic hippocampal neuronal preparations 
decreased 2-AG-mediated DSE as well as the inhibition of excitatory post-synaptic currents 
elicited by exogenous application of 2-AG, consistent with our hypothesis that CRIP1a attenuates 
CB1 receptor signaling.  
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 The same [35S]GTPγS binding conditions described previously for the cerebellum were used 
to evaluate the hippocampus of CRIP1a WT and KO mice (Figure 14).  Two-way ANOVA of the 
concentration-effect curves showed no significant main effect of genotype in this region with 
either CP55,940 or NE.  Furthermore, concentration-effect curves for CP55,940 and NE showed 
no differences in Emax or EC50 values between genotypes (Table 4a).  Similar to the cerebellum, 
basal [35S]GTPγS binding was not affected by the absence of CRIP1a, nor was the effect of a 
maximally-effective concentration of SR141716A (Table 4b).  Again, it should be noted that 
only very modest inhibition of [35S]GTPγS binding was observed with 10 nM SR141716A (1-
9%) in this region. 
	  	  	  	  	  The spinal cord is known to express a moderate level of CB1 receptors and play a role in 
mediating antinociceptive effects of cannabinoids (Herkenham et al. 1991, Lichtman and Martin, 
1991).  Moreover, we recently demonstrated that CRIP1a is also expressed in the spinal cord, as 
noted above (see Section 3.1).  Using identical [35S]GTPγS binding conditions to those stated 
above, two-way ANOVA of the CP55,940 or NE concentration-effect curves showed no 
significant differences in the spinal cord between CRIP1a WT and KO mice (Figure 15).  Emax 
and EC50 values were found to not be different between genotypes with either agonist after 
analysis by student’s t-test (Table 5a).  Basal levels of [35S]GTPγS binding in the spinal cord 
were also not different between genotypes (Table 5b).  Results for the single concentration of 10 
nM SR141716A were also not significantly different between genotypes after analysis by two-
tailed t-test (p > 0 .05), although SR141716A essentially had no effect on [35S]GTPγS binding in 
the spinal cord (0-3% inhibition) (Table 5b). 
  
	  	   49 
	  
	   	  
 
Figure 13. Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO cerebellum.  The top 
panel represents concentration-effect curves for CP55,940, while the bottom represents 
concentration-effect curves for noladin ether (NE).  Data are expressed as mean % stimulation ± 
SEM (collapsed by sex, n = 8 per genotype). Two-way ANOVA revealed a significant main 
effect of concentration with CP55,940 (p < 0.0001, F =78.36, df = 7) and NE (p < 0.0001, F = 
109.0,  df = 7) and a significant main effect of genotype with CP55,940 (p < 0.05, F = 5.08, df = 
1), but only a trend toward significance with NE (p = 0.0889, F = 2.985, df = 1).  No significant 
interactions were observed with CP55,940 or NE. 
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Table 3a. Emax and EC50 Values Derived From Agonist-Stimulated [35S]GTPγS Binding in 
the Cerebellum. 
 
 
 
 
Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO cerebellum shows no differences 
in Emax or EC50 values between genotypes for CP55,940 and NE.  Data are mean Emax and EC50 
values ± SEM, derived from the concentration-effect curves shown in Figure 13 (collapsed by 
sex, n = 8).  After two-tailed t-test, data were determined to not be significantly different (p > 
0.05).  
 
 
 
Table 3b.  Basal and SR141716A-inhibited [35S]GTPγS Binding in the Cerebellum.  
 
Basal  (fmol/mg)  SR141716A (% Stimulation) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
101 ± 9 99 ± 7 -17.6 ± 3.3  -11.0 ± 2.2 
 
 
[35S]GTPγS binding in CRIP1a WT and KO cerebellum shows no differences between genotypes 
for basal or in the presence of the CB1 inverse agonist, SR141716A.  Data are represented as 
mean values ± SEM (collapsed by sex, n = 8).  After two-tailed t-test, data were determined to 
not be significantly different (p > 0.05).  
 
 
 
Emax  (% Stimulation) EC50  (nM) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
CP55,940 164 ± 13 143 ± 8   9.7 ± 2.3   8.7 ± 1.1 
NE 191 ± 16   174 ± 10 124 ± 16 123 ± 16 
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Figure 14. Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO hippocampus.  The 
top panel represents concentration-effect curves for CP55,940, while the bottom represents 
concentration-effect curves for NE.  Data are expressed as mean % stimulation ± SEM 
(collapsed by sex, n = 8 per genotype).  Two-way ANOVA revealed a significant main effect of 
concentration with CP55,940 (p < 0.0001, F = 39.99, df = 7) and NE (p < 0.0001, F = 34.92, df = 
7).  No statistically significant interactions or main effect of genotype were observed for 
CP55,940 or NE.  
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Table 4a. Emax and EC50 Values Derived From Agonist-Stimulated [35S]GTPγS Binding in 
the Hippocampus. 
 
 
 
 
 
 
 
 
 
Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO hippocampus shows no 
differences in Emax or EC50 values between genotypes for CP55,940 and NE.  Data are mean Emax 
and EC50 values ± SEM, derived from the concentration-effect curves shown in Figure 14 
(collapsed by sex, n = 8).  After two-tailed t-test, data were determined to not be significantly 
different (p > 0.05).  
 
 
Table 4b.  Basal and SR141716A-inhibited [35S]GTPγS Binding in the Hippocampus. 
 
Basal  (fmol/mg) SR141716A (% Stimulation) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
163 ± 20 159 ± 14 -9.1 ± 6.7 -1.3 ± 2.3 
 
 
[35S]GTPγS binding in CRIP1a WT and KO hippocampus shows no differences between 
genotypes for basal or in the presence of the CB1 inverse agonist, SR141716A. Data are 
represented as mean values ± SEM (collapsed by sex, n = 8).  After two-tailed t-test, data were 
determined to not be significantly different (p > 0.05).  
 
	  
	  
 
Emax  (% Stimulation) EC50  (nM) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
CP55,940 75 ± 8 76 ± 5 5.1 ± 0.6 3.9 ± 0.2 
NE 82 ± 7 80 ± 6 67.7 ± 21.3 32.0 ± 3.2 
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Figure 15. Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO spinal cord.  The top 
panel represents concentration-effect curves for CP55,940, while the bottom represents 
concentration-effect curves for NE.  Data are expressed as mean % stimulation ± SEM 
(collapsed by sex, n = 8 per genotype).  Two-way ANOVA revealed a significant main effect of 
concentration with CP55,940 (p < 0.0001, F = 82.52, df = 7) and NE (p < 0.0001, F = 177.5,  df 
= 7).  No significant interactions or main effect of genotype were observed with CP55,940 or 
NE. 
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Table 5a. Emax and EC50 Values Derived From Agonist-Stimulated [35S]GTPγS Binding in 
the Spinal Cord.   
 
 
 
 
 
 
Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO spinal cord shows no differences 
in Emax or EC50 values between genotypes for NE and CP55,940.  Data are mean Emax and EC50 
values ± SEM, derived from the concentration-effect curves shown in Figure 15 (collapsed by 
sex, n = 8).  After two-tailed t-test, data were determined to not be significantly different (p > 
0.05).  
 
Table 5b.  Basal and SR141716A-inhibited [35S]GTPγS Binding in the Spinal Cord.  
 
Basal  (fmol/mg) SR141716A (% Stimulation) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
151 ± 14 161 ± 17 -2.9 ± 2 -1.7 ± 1 
 
[35S]GTPγS binding in CRIP1a WT and KO spinal cord shows no differences between genotypes 
for basal or in the presence of the CB1 inverse agonist, SR141716A.  Data are represented as 
mean values ± SEM (collapsed by sex, n = 8).  After two-tailed t-test, data were determined to 
not be significantly different (p > 0.05).  
 
 
3.5 Agonist-Stimulated [35S]GTPγS Binding Reveals Increased CB1-Mediated G-Protein 
Activity in the Amygdala of CRIP1a KO Relative to WT Mice.  
     After no differences were found between genotypes in the cerebellum and hippocampus, we 
continued surveying CB1 receptor-expressing CNS regions known to be involved in mediating 
various effects of cannabinoids, and in which CRIP1a expression has been observed.  The 
 
Emax  (% Stimulation) EC50  (nM) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
CP55,940 48 ± 3 56 ± 7   9.9 ± 0.9    8.7 ± 1.6 
NE 57 ± 4 60 ± 4 166 ± 19 209 ± 37 
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amygdala is a brain region involved in regulating anxiety and conditioned fear responses, which 
are modulated by cannabinoid agonists (Barad et al. 2006; Davidson, 2002).  Therefore, 
cannabinoid agonist-stimulated [35S]GTPγS binding was examined using identical conditions as 
described in section 3.4.  My hypothesis that the loss of CRIP1a could produce an enhanced 
response to cannabinoid agonists had not been realized in the regions previously examined, yet 
interestingly, results in the amygdala revealed enhanced CB1 receptor-mediated G-protein 
activation in CRIP1a KO relative to WT mice.  Concentration-effect curves for CP55,940 and NE 
each showed greater CB1 receptor-mediated stimulation of [35S]GTPγS binding in amygdala of 
CRIP1a KO mice (Figure 16), and these results were confirmed by two-way ANOVA, which 
showed a significant main effect of genotype for CP55,940 (p = 0.0001, F = 19.46, df = 1) and 
NE (p < 0.0001, F = 128.3,  df = 1).  In addition to a main effect of genotype, Bonferroni post-
hoc tests showed enhanced CP55,940-mediated stimulation at 0.03, 0.1, 0.3 and 1 µM, while NE 
showed enhanced stimulation at 0.1, 0.3 and 1 µM, in CRIP1a KO relative to WT mice (Figure 
16).  Emax values for both agonists were significantly greater in CRIP1a KO compared to WT 
mice (Table 6a).  No difference in potency, however, which is indicated by a leftward or 
rightward shift of the curve, was observed for either agonist.  EC50 values for both agonists were 
found to not be statistically different between WT and KO mice with either agonist (Table 6a).  
Basal [35S]GTPγS binding and the single concentration of 10 nM SR141716A were also not 
statistically different between genotypes (Table 6b), although SR141716A had minimal effects 
on [35S]GTPγS binding, similar to the other regions examined.   
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Figure 16. Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO amygdala.  The top 
panel represents concentration-effect curves for CP55,940, while the bottom panel represents 
concentration-effect curves for NE.  Data are expressed as mean % stimulation ± SEM 
(collapsed by sex, n = 6 per genotype). Two-way ANOVA revealed a significant main effect of 
concentration with CP55,940 (p < 0.0001, F = 50.39, df = 7) and NE (p < 0.0001, F = 88.79,  df 
= 7).  Two-way ANOVA also revealed a significant main effect of genotype with CP55,940 (p = 
0.0001, F = 19.46, df = 1) and NE (p < 0.0001, F = 88.79, df = 1). No significant interactions 
were observed with CP55,940 or NE. 	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Table 6a. Emax and EC50 Values Derived From Agonist-Stimulated [35S]GTPγS Binding in 
the Amygdala.   
 
 
 
 
 
 
 
 
 
 
Table 6.  Agonist-stimulated [35S]GTPγS binding in CRIP1a WT and KO amygdala revealed 
statistically significant differences between genotypes in Emax values for CP55,940 and NE.  
Data are mean Emax and EC50 values derived from the concentration-effect curves shown in 
Figure 16 ± SEM (collapsed by sex, n = 6).  Analysis with two-tailed t-test revealed significant 
differences between genotypes for CP55,940 Emax values (**p < 0.01) and NE Emax values (*p < 
0.05), but not for EC50 values of either ligand (p > 0.05).  
 
 
Table 6b.  Basal and SR141716A-inhibited [35S]GTPγS Binding in the Amygdala.  
 
Basal  (fmol/mg)  SR141716A (% Stimulation) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
101 ± 22 108 ± 12 -1 ± 4 9 ± 5 
 
 
[35S]GTPγS binding in CRIP1a WT and KO amygdala shows no differences between genotypes 
for basal or in the presence of the CB1 inverse agonist, SR141716A.  Data are represented as 
mean values ± SEM (collapsed by sex, n = 6).  After two-tailed t-test, data were determined to 
not be significantly different (p > 0.05).  
 
  
 
Emax  (% Stimulation) EC50  (nM) 
CRIP1a WT CRIP1a KO CRIP1a WT CRIP1a KO 
CP55,940 72 ± 4 95 ± 4**   6.2 ± 0.9   5.1 ± 0.7 
NE 72 ± 2 99 ± 5* 50.3 ± 14 22.1 ± 8.0 
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3.6 CRIP1a KO Mice Do Not Show a Unique Baseline Phenotype Compared to WT 
Littermate Controls in Spontaneous Locomotor Activity.  
       It is well documented that cannabinoid agonists induce acute locomotor suppressive effects 
(Crawley et al. 1993).  To determine whether the absence of CRIP1a affects locomotor activity, 
CRIP1a WT and KO mice were placed in open field test chambers and allowed to explore the 
area for 30 minutes.  Activity was recorded using Fire-i™ digital cameras and ANY-maze™ 
tracking software.  The 30-minute time period was evaluated both as a whole time span and as 
three separate 10-minute bouts of activity, measured in seconds.  Time spent mobile, time spent 
immobile and time spent freezing were all recorded and compared between genotypes.  No 
significant differences between genotypes were found for any of the measures recorded.  Over a 
total test time of 30 minutes, CRIP1a WT mice were mobile for approximately 83% of the time, 
while CRIP1a KO mice were mobile for approximately 79% of the time (collapsed by sex, n =8 
per genotype; Figure 17a).  Time spent immobile was also not different, as CRIP1a WT mice 
were immobile for approximately 17% of the time, versus CRIP1a KO mice that were immobile 
for approximately 21% of the time (Figure 17b).  Immobility was often due to mice grooming, 
therefore no movement across the x-y plane occurred, but the mouse was not completely still. 
There were also no significant differences between genotypes in the time spent freezing, 
whereby the mice were essentially completely still.  CRIP1a WT mice were considered to exhibit 
freezing behavior for a total of 66 ± 28 seconds whereas CRIP1a KO mice displayed freezing 
behavior for a total of 136 ± 73 seconds (Figure 17c).  Although the total time spent freezing by 
CRIP1a KO mice was approximately twice that of WT mice, high variability in the results for this 
measure led to a lack of statistical significance. 
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     When broken down into 10-minute individual periods, there were still no differences between 
genotypes at each segment, but there were significant differences between the segments 
themselves.  This could be due to habituation, whereby the environmental novelty wears off and 
the mice stop avidly exploring.  In the first 10 minutes, CRIP1a WT mice were mobile for 94.5% 
of the time, compared to CRIP1a KO mice that were mobile for approximately 92% of the time 
(Table 7).  CRIP1a WT mice spent the remaining 5.5% of the time immobile, which was similar 
to the CRIP1a KO mice that spent their approximate 8% of remaining time immobile. Freezing 
behavior was negligible, since both CRIP1a KO and WT mice were “frozen” for only an average 
of approximately two seconds during the first segment (Table 8).   
     The second segment of the test saw a marked reduction in the amount of time mice spent 
mobile, and thus increases in both time spent immobile and freezing.  CRIP1a WT mice were 
mobile for 84%, while CRIP1a KO mice were mobile for 76% of the time (Table 7).  No 
differences between genotypes were observed after two-way ANOVA (p > 0.05).  CRIP1a WT 
mice spent significantly more time immobile in segment 2 compared to segment 1, at 
approximately 16% of the time, as determined by one-way ANOVA followed by Newman-Keuls 
post-hoc test (p = 0.0137, F = 24.71, R2 = 0.9428).  Alternatively, CRIP1a KO mice did not spend 
significantly more time immobile in segment 2 (approximately 23%) when compared to segment 
1 after analysis with one-way ANOVA (p = 0.0542), although they showed a trend toward 
greater time immobile, but high variability was a factor.  There were also no significant 
differences between genotypes for time spent immobile within segment 2 as determined by one-
way ANOVA followed by Newman-Keuls post-hoc test, p > 0.05).  Time spent freezing 
increased between segment 1 and 2, although no significant main effects of genotype or test 
segment were observed (two-way ANOVA, p > 0.05) (Table 8).  
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The time spent mobile in segment 3 was significantly lower for both genotypes compared to 
the time spent mobile in segment 1 (two-way ANOVA, p < 0.001), with robust significance 
reached in the CRIP1a WT mice (two-way ANOVA followed by Bonferroni post-hoc test, p < 
0.001) (Table 7).  No main effect of genotype was observed however, as total time spent mobile 
in segment 3 was approximately 71% in the CRIP1a WT mice while CRIP1a KO mice were 
mobile for a total of about 70% (Table 7).  Since time mobile and time immobile are inversely 
related, it is not surprising that time spent immobile significantly increased across segments for 
both genotypes.  CRIP1a WT mice were immobile for nearly 29% of the time, whereas CRIP1a 
KO mice were immobile for 30% of the time.  Similar to time mobile, statistically significant 
results were observed after analysis by two-way ANOVA, which revealed a main effect of test 
segment, but not genotype, between segments 1 and 3 for both CRIP1a WT and KO mice.  Time 
spent freezing however, was determined to not be statistically different between genotypes or 
across test segments after two-way ANOVA, p > 0.05 (Table 8). 
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Figure 17. Measures of spontaneous locomotor activity in CRIP1a WT and KO mice.  Two-tailed 
t-test revealed no significant differences between genotypes for total time spent mobile (A), time 
spent immobile (B) or time spent freezing (C) during the 30-minute test (p > 0.05). Data are 
expressed as mean time ± SEM, n = 8 per genotype.  
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Table 7.  Spontaneous Locomotor Activity: Time Spent Mobile by Segment of Test. 
 
 
 
 
 
 
Spontaneous locomotor activity decreased over time, but no significant genotype effects were 
observed in CRIP1a KO compared to CRIP1a WT mice.  Data are expressed as mean ± SEM for 
each segment.  Results showed a main effect of test segment after two-way ANOVA (p = 
0.0002, F = 10.47, df = 2), but no interactions or main effect of genotype (p > 0.05) were 
observed. Bonferroni post-hoc analysis revealed significant differences between the first and 
second test segment in CRIP1a WT mice (* p < 0.05) and significant differences between the first 
and final test segments for both CRIP1a WT and KO mice (* p < 0.05, ** p < 0.01).  
  
 
Table 8.  Spontaneous Locomotor Activity: Average Time Spent Freezing by Segment of 
Test. 
 
 
 
 
 
 
 
Average time spent freezing was not different in CRIP1a KO compared to CRIP1a WT mice.  
Data are expressed as mean ± SEM for each test segment.  Results reveal no significant 
interactions and no main effects of genotype or test segment after two-way ANOVA (p > 0.05).     
 
 
Time Mobile (seconds)  
0-600 sec 600-1200 sec 1200-1800 sec 
CRIP1a WT  567 ± 9   503 ± 12 *  428 ± 30 ** 
CRIP1a KO  553 ± 6 458 ± 42  418 ± 49 * 
 
Time Freezing (seconds)  
0-600 sec 600-1200 sec 1200-1800 sec 
CRIP1a WT  2.4 ± 1.6 9 ± 4  32 ± 13  
CRIP1a KO  2.5 ± 1.2 21 ± 14  17 ± 12 
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3.7 CRIP1a KO Mice Do Not Show a Unique Phenotype Compared to WT Littermate 
Controls in Motor Coordination.  
     Cannabinoid agonists not only disrupt spontaneous locomotor activity, but also locomotor 
coordination (De Santy and Dar, 2001).  To test whether the absence of CRIP1a affects motor 
coordination, mice were trained to perform on a RotaRod at a moderately low rpm of 10, and 
later tested at a slightly higher rpm of 16.  Data were collected from the time the drum began 
spinning until the time the mouse fell, jumped, or engaged in a passive rotation.  Rotation 
velocity was held constant at 16 rpm.  CRIP1a KO mice performed on average the same as WT 
mice, with an average time to fall equaling 21.1 ± 3.5 seconds compared to the CRIP1a WT 
average of 19.6 ± 6.2 seconds (Figure 18a).  These latencies did not differ between genotypes, as 
determined by two-tailed t-test (p > 0.05).  Distance traveled was also measured, and was found 
not to differ between genotypes after two-tailed t-test (p > 0.05).  CRIP1a WT mice traveled an 
average of 0.54 ± 0.17 meters while CRIP1a KO mice traveled an average of 0.57 ± 0.10 meters 
(Figure 18b).  
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Figure 18. CRIP1a WT and KO mice do not differ in RotaRod assessment of motor coordination.  
Time to fall (A) and distance traveled (B) were not statistically different between CRIP1a WT 
and KO mice after two-tailed t-test (p > 0.05).  Data represented are mean time (A) or distance 
(B) ± SEM, n = 8 per genotype. 
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3.8 CRIP1a KO Mice Do Not Show a Unique Phenotype Compared to WT Littermate 
Controls in the Hotplate Assessment of Antinociception.  
     Current proposed medicinal uses of cannabinoids include pain relief, and it is known that 
cannabinoid agonists can reduce responses to nociceptive stimuli through spinal- and supra-
spinally-mediated pathways (Lichtman et al. 1991). Therefore, it was of interest to evaluate in 
vivo measures of antinociception in CRIP1a WT and KO mice to determine if loss of CRIP1a 
affects baseline pain thresholds due to potential changes in CB1 receptor activity.  The mice were 
evaluated for response latencies to a hot plate set at 52º or 56ºC, two temperatures commonly 
used to assess thermal antinociception in the literature (Zimmer et al. 1999).  At 52ºC, CRIP1a 
KO mice responded to the nociceptive stimulus slower than CRIP1a WT mice, but the difference 
between genotypes was not significant after two-tailed t-test analysis (p > 0.05) (Figure 19a).     
     Average response latencies at 56ºC for CRIP1a WT and KO mice were nearly identical, at 
9.04 ± 1.1 seconds and 8.96 ± 1.5 seconds, respectively (Figure 19b).  Two-tailed t-test revealed 
no significant differences between genotypes or between temperatures (p > 0.05).        
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Figure 19. CRIP1a WT and KO mice do not differ in the hot plate assessment of antinociception.  
Mice were tested at 52ºC (A) and 56ºC (B), with response latencies recorded in seconds.  Data 
are mean latencies ± SEM, n = 8 per genotype. Two-tailed t-tests revealed no significant 
difference between genotypes at either temperature setting (p > 0.05).  
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3.9 CRIP1a KO Mice Display an Antinociceptive Phenotype in the Warm Water Tail 
Withdrawal Assay. 
     Contrary to the findings in the hot plate assessment of antinociception, a significant difference 
between genotypes was found in the warm water tail withdrawal assessment of antinociception.  
A water bath set to 52ºC was used to assess tail withdrawal latency in CRIP1a WT and KO mice.  
CRIP1a WT mice displayed a tail withdrawal latency of 1.52 ± 0.12 seconds whereas CRIP1a 
KOs displayed a tail withdrawal latency of 2.14 ± 0.12 seconds (Figure 20a).  Even though the 
average difference between genotypes was just 0.6 seconds, the results were found to be highly 
significant after two-tailed t-test (p < 0.01).  Mice were also assessed at slightly higher (56°C; 
Figure 20b) and lower (48ºC; data not shown) temperatures, however no significant differences 
were observed between genotypes after two-tailed t-test for either temperature (p > 0.05).  
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Figure 20. Warm water tail withdrawal assessment of antinociception in CRIP1a WT and KO 
mice.  CRIP1a KO mice were found to display significantly longer tail withdrawal latencies in 
response to the nociceptive stimulus of a warm water bath set to 52ºC (A) (two tailed t-test, p < 
0.01).  Significant differences between genotypes were no longer observed when the temperature 
was increased to 56ºC (B) (two tailed t-test p > 0.05).  Data represented are mean latencies ± 
SEM (n = 8 per genotype).   
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3.10 CRIP1a KO Mice Display an Anxiolytic-like Phenotype in the Light:Dark Box and 
Marble Burying Assays.   
     Cannabinoids elicit biphasic effects with regard to anxiety-like behaviors.  Current evidence 
indicates these effects are due to a CB1 receptor-mediated role in the amygdala, hippocampus 
and prefrontal cortex (Davidson, 2002; Braun et al. 2003).  In addition, there is evidence that not 
only can exogenous cannabinoids affect anxiety-like behaviors, but also the endocannabinoids 
may play a role.  For example, FAAH KO mice were shown to display an anxiolytic-like 
phenotype (Cravatt and Lichtman, 2003), likely a result of elevated anandamide levels.  This 
effect was shown to be CB1 receptor-mediated, as it was reversible by SR141716A.  Moreover, 
the results of [35S]GTPγS binding assays revealed significantly greater G-protein activation by 
CB1 receptors in the amygdala of CRIP1a KO relative to WT mice (see Section 3.5).  Therefore, 
naïve CRIP1a WT and KO mice were evaluated for possible anxiety-related phenotypes.  A 
robust and repeatable anxiolytic-like phenotype was observed in CRIP1a KO compared to WT 
mice (Figure 21) in the light:dark box assay.  Within the five-minute time period of this test, 
CRIP1a KO mice spent an average of 178 ± 20 seconds in the light side, which was significantly 
greater than CRIP1a WT mice, which spent an average of 111 ± 11 seconds in the light side (two-
tailed t-test, p < 0.01).  Video tracking ensured that no deficits in locomotor activity contributed 
to the findings (Figure 22), confirming previous results that indicated no differences between 
genotypes in open field locomotor activity (see section 3.6).      
     Based on the finding of an anxiolytic-like phenotype in CRIP1a KO mice in the light:dark box 
test, it was important to determine whether other measures of anxiety-related behaviors would 
yield similar results.  This was particularly important because animals tested in the light:dark box 
assay could not be reexamined in the same conditions due to habituation, thus repeating the test 
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would have required a new cohort of test-naïve mice.  Another common behavioral assay used to 
measure anxiety-related behaviors is marble burying.  Typical murine digging behavior leads to 
many of the marbles being buried in loose pine bedding, however under the influence of 
anxiolytic drugs such as benzodiazepines, mice bury significantly fewer marbles (Njung'e and 
Handley, 1991).  After assessing naïve CRIP1a WT and KO mice in the marble-burying test, a 
significant anxiolytic-like phenotype was observed in the KO relative to WT mice (two-tailed t-
test, p < 0.05).  CRIP1a WT mice buried over twice as many marbles on average compared to 
CRIP1a KO mice (Figure 23).   Together with the light:dark box results, these results indicate that 
the absence of CRIP1a produces an anxiolytic-like phenotype in mice. 
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Figure 21. CRIP1a KO mice spend more time in the light side compared to CRIP1a WT mice.  
CRIP1a WT and KO mice (n = 8 per genotype, collapsed by sex) were placed in a light:dark box 
chamber and allowed to freely explore both compartments for five minutes. Time spent in either 
side was recorded using the video-tracking software, ANY-maze™, and total time in each 
compartment was measured in seconds.  Data represented are mean time spent in the light side ± 
SEM.  CRIP1a KO mice spent significantly more time (two-tailed student’s t-test, p < 0.05) in the 
light side compared to WT mice, suggesting an anxiolytic-like phenotype.   
 
 
 
 
Time Spent in Light Side
WT KO
0
50
100
150
200
Se
co
nd
s
Genotype
WT
KO
*
	  	   72 
 
 
 
Figure 22. CRIP1a WT and KO mice do not differ in time spent mobile during light:dark box 
assay.  CRIP1a WT and KO mice (n = 8 per genotype, collapsed by sex) were placed in a 
light:dark box chamber and allowed to freely explore both compartments for five minutes. Time 
spent in either side was recorded using the video-tracking software, ANY-maze™, and total time 
in each compartment was measured in seconds and summed.  Data represented are mean time 
mobile ± SEM.  No significant differences were observed after two-tailed student’s t-test, p > 
0.05.  
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Figure 23. CRIP1a KO mice bury less marbles compared to CRIP1a WT mice.  CRIP1a WT and 
KO mice (n = 16 KO and 13 WT mice, collapsed by sex) were placed in a cage containing 20 
evenly spaced marbles on fluffed bedding. After twenty minutes, total marbles buried was 
assessed.  Data represented are mean number of marbles buried ± SEM.  CRIP1a KO mice buried 
significantly less marbles (two-tailed student’s t-test, p < 0.05) compared to WT mice, 
suggesting an anxiolytic-like phenotype.   
 
 
3.11 CRIP1a KO Mice Do Not Show a Unique Phenotype Compared to WT Littermate 
Controls in the Tetrad Assay After Cumulative Doses of CP55,940.   
     CRIP1a WT and KO mice have thus far been assessed solely in a naïve state.  With the 
exception of anxiolytic-like behavior, the findings have yielded either small effects (see section 
3.7) or no significant differences between genotypes.  It is possible that further phenotypic 
differences related to loss of CRIP1a could be unmasked by activating CB1 receptors with an 
agonist.  Based on our laboratory’s results using CRIP1a over-expression in cell culture models, 
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which showed CRIP1a reduced agonist-stimulated CB1 receptor-mediated G-protein activity, a 
lack of CRIP1a could affect in vivo results by producing exaggerated agonist effects due to the 
absence of CRIP1a-mediated negative regulation of CB1 receptor activation.  Of the CNS regions 
examined so far, however, only the amygdala revealed an enhancement of CB1 receptor-
mediated G-protein activation in CRIP1a KO relative to WT mice.  However, it is possible that a 
life-long absence of CRIP1a might have caused adaptation in CB1 receptor-mediated G-protein 
activation, which could have masked the expected effect of CRIP1a deletion.  Because such 
compensatory adaptation is less likely in mice that are heterozygous for the KO allele, CRIP1a 
HET mice could potentially exhibit an enhanced sensitivity to cannabinoid agonists.  Therefore, 
CRIP1a WT, HET and KO male mice were evaluated in a cumulative dosing tetrad paradigm 
using the potent synthetic cannabinoid agonist, CP55,940 (n = 8 per genotype).  Mice were 
examined for baseline responses in the following measures: catalepsy, warm water tail 
withdrawal, hot plate, RotaRod performance and body temperature.  These measures were 
repeatedly evaluated after each increasing dose of CP55,940 was administered, to assess dose-
response effects in our mice.  The actual doses that were administered to mice were designed 
such that together, they cumulatively equaled the test doses shown below.  
Catalepsy was first observed in CRIP1a WT and HET males after receiving a total of 
0.03mg/kg CP 55,940.  The CRIP1a KO mice did not exhibit catalepsy until the 0.1mg/kg dose.  
All genotypes were equally affected at the 0.3 mg/kg dose and final dose of 1mg/kg, whereby 
many mice remained motionless for the full 60 seconds.  Therefore, catalepsy was not 
exaggerated in the CRIP1a KO mice; in fact, they displayed a slightly reduced sensitivity to 
CP55,940 in this measure (Figure 24), although this apparent difference did not reach the level of 
statistical significance, as indicated by the findings of no significant main effect of genotype nor 
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an interaction between dose and genotype after analysis by two-way ANOVA.  Data were then 
transformed to a percentage of the maximum possible effect (%MPE), with a cut-off time of 60 
seconds.  However, no differences were seen among genotypes using this normalization of the 
data.  Only a main effect of CP55,940 dose was determined to be significant by two-way 
ANOVA (p < 0.0001, F = 108.1, df = 3), while no interactions between dose and genotype were 
observed.   
Baseline tail withdrawal latencies at 52ºC were not significantly different among genotypes 
as determined by two-way ANOVA (p > 0.05), differing from previously observed results (see 
section 3.7).  Significant effects among genotypes were also not observed for tail withdrawal 
latency upon cumulative dosing with CP55,940.  No main effect of genotype was found in either 
the raw latency data or the data transformed to % MPE (Figure 25), when analyzed by two-way 
ANOVA (p > 0.05).  No interactions were observed either, however a main effect of CP55,940 
dose was found (p < 0.0001, F = 65.33, df = 5). 
A second measure of antinociception was evaluated using a hot plate set to 52ºC. Baseline 
latencies were slightly higher in CRIP1a KOs, but not significantly different (one-way ANOVA 
with Newman-Keuls post hoc, p > 0.05), similar to previous results (see section 3.8).  By the 
final CP55,940 dose of 1 mg/kg, a ceiling effect prevented any potential genotype differences 
from being observed, as each mouse reached the maximum cut-off time of 20 seconds without 
responding to the nociceptive stimulus.  No significant differences among genotypes were 
observed, as indicated by the finding of no significant main effect of genotype after analysis by 
two-way ANOVA (p > 0.05).  Transforming data to %MPE also revealed no differences among 
genotypes (Figure 26).  Similar to the previously reported behaviors, no interactions were 
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observed, however a main effect of CP55,940 dose was determined by two-way ANOVA (p < 
0.0001, F = 32.88, df = 5). 
Motor coordination was assessed using an accelerating RotaRod protocol starting at 6 RPM 
and increasing to 25 RPM over a period of 60 seconds.  Both maximum RPM and time to stay on 
the RotaRod drum (in seconds) were recorded for baseline and at each dose of CP55,940 (Figure 
27).  Surprisingly, CRIP1a KO mice exhibited longer average times on the RotaRod than either 
WT or HET mice throughout the course of the experiment, though no significant main effect was 
obtained among genotypes after two-way ANOVA (p > 0.05).  Not until the maximum assessed 
dose of 1 mg/kg CP55,940 were there apparent deficits in motor coordination.  Two-way 
ANOVA revealed a significant main effect of CP55,940 dose (p = 0.0002, F = 5.26, df = 5), but 
no interactions.   
 The final output measure was change in core body temperature.  As expected, temperatures 
declined with increasing doses of CP55,940, however no significant main effect was obtained 
between genotypes after two-way ANOVA (p > 0.05) (Figure 28).  A main effect of CP55,940 
dose was observed (p < 0.0001, F = 128.4, df = 5), though no interactions were revealed.  Thus, 
these results indicate no significant effects of CRIP1a deletion on several prototypical 
pharmacological actions of cannabinoid agonists, including catalepsy, thermal antinociception, 
hypothermia or motor incoordination. 
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Figure 24. Change in cataleptic behavior during cumulative dosing with CP55,940 in CRIP1a 
WT, HET and KO male mice (n = 8 per genotype).  After baseline latencies were measured, 
intraperitoneal (i.p.) injections of increasing CP55,940 doses were administered and a 30 minute 
incubation period elapsed prior to assessing catalepsy at each dose.  Data represented are mean 
values ± SEM. Two-way ANOVA revealed a significant main effect of dose (p < 0.0001, F = 
108.1, df = 5). No significant interactions or main effect of genotype were observed (p > 0.05). 	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Figure 25. Change in latency to withdraw tail from a 52°C warm water bath during cumulative 
dosing with CP55,940 in CRIP1a WT, HET and KO male mice (n = 8 per genotype).  Mice were 
evaluated for antinociception.  After baseline latencies were measured, intraperitoneal (i.p.) 
injections of increasing CP55,940 doses were administered and a 30 minute incubation period 
elapsed prior to assessing antinociception at each dose.  Data represented are mean values ± 
SEM.  Two-way ANOVA revealed a significant main effect of dose (p < 0.0001, F = 65.33, df = 
5). No significant interactions or main effect of genotype were observed (p > 0.05). 	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Figure 26. Change in response times to a 52°C hot plate during cumulative dosing with 
CP55,940 in CRIP1a WT, HET and KO male mice (n = 8 per genotype).  Mice were evaluated 
for antinociception.  After baseline latencies were measured, intraperitoneal (i.p.) injections of 
increasing CP55,940 doses were administered and a 30 minute incubation period elapsed prior to 
assessing antinociception at each dose.  Data represented are mean values ± SEM. Two-way 
ANOVA revealed a significant main effect of dose (p < 0.0001, F = 32.88, df = 5). No 
significant interactions or main effect of genotype were observed (p > 0.05). 	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Figure 27. Change in motor coordination during cumulative dosing with CP55,940 in CRIP1a 
WT, HET and KO male mice (n = 8 per genotype).  After baseline measures were recorded, 
intraperitoneal (i.p.) injections of increasing CP55,940 doses were administered and a 30 minute 
incubation period elapsed prior to assessing motor coordination at each dose via accelerating 
RotaRod.  Data represented are mean values ± SEM.  Two-way ANOVA revealed a significant 
main effect of dose (p = 0.0002, F = 5.26, df = 5). No significant interactions or main effect of 
genotype were observed (p > 0.05). 	  
 
 
RotaRod: Average Max RPM
0 0.01 0.03 0.1 0.3 1
0
5
10
15
20
R
PM
 (r
/m
in
)
CP 55,940 dose (mg/kg) 
WT
HET
KO
RotaRod: Average Time to Fall
0 0.01 0.03 0.1 0.3 1
0
10
20
30
40
Se
co
nd
s
CP 55,940 dose (mg/kg) 
WT
HET
KO
	  	   81 
 
 
 
Figure 28. Change in core body temperature during cumulative dosing with CP55,940 in CRIP1a 
WT, HET and KO male mice (n = 8 per genotype).  Mice were evaluated for core body 
temperature using a digital rectal probe.  After baseline body temperature was measured, 
intraperitoneal (i.p.) injections of increasing CP55,940 doses were administered and a 30 minute 
incubation period elapsed prior to assessing body temperature at each dose.  Data represented are 
mean values ± SEM. Two-way ANOVA revealed a significant main effect of dose (p < 0.0001, F 
= 128.4, df = 5). No significant interactions or main effect of genotype were observed (p > 0.05). 	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3.12 CRIP1a Expression is Not Affected by Repeated THC Treatment or by Genetic 
Knockout of CB1 Receptors in Mice.   
     I previously showed that CRIP1a is present in the cerebellum, hippocampus and the spinal 
cord, but other regions of the brain have not been specifically investigated.  Moreover, the effect 
of prolonged activation or genetic deletion of CB1 receptors on the expression of CRIP1a in CB1 
receptor-expressing regions of the CNS has not been investigated.  Therefore, CB1 WT and KO 
male mice were treated chronically with either vehicle (VEH) or 10 mg/kg THC twice a day for 
13.5 days – a standard dosing treatment used to activate CB1 receptors and potentially induce 
adaptation in expression or activity of CB1 receptors – after which CRIP1a expression was 
analyzed for differences between treatment groups and genotypes in the amygdala, cerebellum 
and prefrontal cortex.  Each of these regions expresses moderate-to-high levels of CB1 receptors 
and plays various roles in mediating behavioral effects of cannabinoids (Herkenham et al. 1991; 
Rubino et al. 2008; Bambico et al. 2007).  It is important to determine whether CRIP1a 
expression is altered when CB1 receptors are not present by examining VEH-treated CB1 
receptor KO and WT mice, and additionally if it is affected by prolonged activation of CB1 
receptors, as determined in THC-treated mice.  These two factors provide an initial indication of 
the extent to which CRIP1a levels are affected by alterations of CB1 receptor expression or 
activity in a subset of brain regions, and therefore whether CRIP1a expression could be regulated 
by the status of the endocannabinoid system. 
Western immunoblots were performed under [my] supervision by a rotation student, 
Cassandra Slater, and showed CRIP1a presence does not statistically differ in the cerebellum, 
prefrontal cortex or amygdala of CB1 WT and KO mice or between VEH and THC treatments 
(Figure 29, 30 and 31).  A slight trend toward increased CRIP1a expression was observed in the 
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cerebellum of both VEH- and THC-treated CB1 KO mice (main effect of genotype by two-way 
ANOVA, p = 0.133), however no interaction or main effect of treatment was observed (p > 0.05) 
(Figure 29).  In both the prefrontal cortex (Figure 30) and amygdala (Figure 31), expression was 
nearly identical across treatment conditions and genotypes.  After two-way ANOVA, no 
interaction or main effects of genotype or treatment were found with regard to either region (p > 
0.05).   These results indicate that CRIP1a expression is not dependent on the expression of CB1 
receptors and is not altered by repeated administration of 10 mg/kg THC, at least in these 
particular brain regions. 
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Figure 29. Expression of CRIP1a in the cerebellum is not affected by CB1 receptor KO or 
repeated THC treatment.  Representative immunoblots of CRIP1a protein in cerebellum (top 
panel) shows expression in CB1 WT and KO vehicle-treated and THC-treated mice (n=8 per 
genotype, per treatment). WT-V and WT-T represent WT vehicle-treated and THC-treated mice, 
respectively.  KO-V and KO-T represent KO vehicle-treated and THC-treated mice, respectively.  
Relative densities (bottom panel) were measured from blots and analyzed by two-way ANOVA.  
No significant main effects of treatment or genotype were observed, nor was there an interaction 
(p > 0.05).  
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Figure 30. Expression of CRIP1a in the prefrontal cortex is not affected by CB1 receptor KO or 
repeated THC treatment.  Representative immunoblots of CRIP1a protein in prefrontal cortex (top 
panel) shows expression in CB1 WT and KO vehicle-treated and THC-treated mice (n=8 per 
genotype, per treatment). WT-V and WT-T represent WT vehicle-treated and THC-treated mice, 
respectively.  KO-V and KO-T represent KO vehicle-treated and THC-treated mice, respectively.  
Relative densities (bottom panel) were measured from blots and analyzed by two-way ANOVA.  
No significant main effects of treatment or genotype were observed, nor was there an interaction 
(p > 0.05).  
 
Prefrontal Cortex
WT VEH WT THC KO VEH KO THC
0
10
20
30
40
50
R
el
at
iv
e 
D
en
si
ty
Genotype
WT VEH
WT THC
KO VEH
KO THC
Cerebellum!
CRIP1a  !
18 kDa!
WT-V    WT-T      KO-V    KO-T    !
α-tubulin !
50 kDa!
A 
α-tubulin !
50 kDa!
CRIP1a  !
18 kDa!
Prefrontal Cortex!
KO-T      KO-V     WT-T    WT-V!
B 
α-tubulin !
50 kDa!
Amygdala!
    WT-V    WT-T     KO-V    KO-T   !
CRIP1a  !
18 kDa!
C 
α
-
	  	   86 
 
 
 
 
Figure 31. Expression of CRIP1a in the amygdala is not affected by CB1 receptor KO or repeated 
THC treatment.  Representative immunoblots of CRIP1a protein in amygdala (top panel) shows 
expression in CB1 WT and KO vehicle-treated and THC-treated mice (n=8 per genotype, per 
treatment). WT-V and WT-T represent WT vehicle-treated and THC-treated mice, respectively.  
KO-V and KO-T represent KO vehicle-treated and THC-treated mice, respectively.  Relative 
densities (bottom panel) were measured from blots and analyzed by two-way ANOVA.  No 
significant main effects of treatment or genotype were observed, nor was there an interaction (p 
> 0.05).   
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Chapter 4. Discussion and Conclusions 
 
4.1 Overview. 
     The purpose of this thesis project was to investigate the physiological role(s) of CRIP1a in the 
whole animal by using the first ever CRIP1a knockout mouse line.  To generate the first CRIP1a 
KO mice, CRIP1a HET mice (generated by the initial chimeric mice) were placed in breeding 
pairs.	  	   Our first litter contained CRIP1a WT, HET and KO mice, determined by genotyping with 
PCR and specific primers.  In order to demonstrate that Cnrip1 gene-targeted mice were in fact 
null for CRIP1a expression, several experiments were preformed.  First, Western immunoblot 
analysis of cerebellar homogenates probed with CRIP1a antiserum showed robust expression in 
the CRIP1a WT mouse, whereas a complete absence of CRIP1a was observed in the CRIP1a KO 
mouse, even up to 100 µg of protein.  We also evaluated immunoblots of the hippocampus and 
spinal cord of CRIP1a KO mice, and again, found no evidence of CRIP1a expression.  Because 
immunoblots represent protein expression, it was important to show that the null status was a 
result of the lack of transcription and not a truncated protein.  qPCR analysis showed that CRIP1a 
KO mice produced a maximum of 0.4% transcript relative to CRIP1a WT mice, further verifying 
that we have a true null Cnrip1 status in these mice.   
Despite the confirmation of CRIP1a null status, Cnrip1 KO mice appeared to be normal and 
viable, as determined by the expected Mendelian ratio of genotypic yield in HET x HET 
crossing.  In addition, these mice were determined to be fertile, as assessed by KO x KO 
crossing, and exhibited a normal rate of growth and development, as assessed by bodyweight 
gain over a 14 week period, from weaning at the age of 3 weeks, to adulthood at the age of 16 
weeks.  
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A standard battery of in vivo assessments was then chosen to evaluate how the absence of 
CRIP1a affects baseline physiological and behavioral status, as well as common pharmacological 
responses after the administration of a cannabinoid agonist.  It is well reported in the literature 
that cannabinoids affect general locomotor activity (Varvel et al. 2006), anxiety-like behaviors 
(Viveros et al. 2005), motor coordination (Desanty and Dar, 2001), and can mediate both spinal 
and supra-spinal components of antinociception (Lichtman et al. 1991, Varvel et al. 2005).  Each 
of these behaviors have also been linked to specific brain regions that appear to play a role in 
these effects.  For example, the cerebellum and striatum are involved in locomotor activity and 
motor coordination (Day et al. 1991; Thach et al. 1992), while the amygdala, hippocampus and 
prefrontal cortex contribute to stress responses and anxiety-like behaviors (Davis, 1992; 
Davidson, 2002; Braun et al. 2003).  Nociception has been linked to regions of the brain such as 
the periaqueductal gray area (PAG) and lateral posterior thalamus, while others have also 
reported a role of the spinal cord (Lichtman et al. 1996; Martin et al. 1999; Welch and Stevens, 
1992). We chose to evaluate a subset of these behaviors in CRIP1a KO mice, both in drug-free 
and cannabinoid agonist-induced states.  Additionally, we evaluated many of these specific 
regions ex vivo through [3H]CP55,940 saturation binding and agonist-stimulated [35S]GTPγS 
binding assays to determine potential genotype-related differences in CB1 receptor levels and 
CB1 receptor-mediated G-protein activity, respectively. 
My major findings were that CRIP1a KO mice exhibit: 1) an anxiolytic-like phenotype, with 
few differences from WT mice in other baseline measures of behavior or physiological status, 2) 
enhanced CB1 receptor-mediated G-protein activation in the amygdala, with only minor or no 
differences from WT mice in other CNS regions examined, 3) no differences in CB1 receptor 
expression levels versus WT mice in any CNS region examined, and 4) no difference from WT 
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mice in pharmacological sensitivity to a cannabinoid agonist in several in vivo measures 
examined.  Furthermore, from the finding that CRIP1a KO mice exhibited either no significant 
differences or enhancement of cannabimimetic effects relative to WT mice in all measures 
examined, we can conclude that CRIP1a does not appear to mediate these effects of CB1 receptor 
activation (i.e. is not required for these actions of cannabinoids).  Finally, neither CB1 receptor 
null status nor repeated administration of THC significantly altered CRIP1a expression in any 
CNS region examined.  Thus, the effects of CRIP1a deletion on CB1 receptor function in the CNS 
appear to be quite specific in nature.  Details of these findings and related interpretations are 
discussed in the following sections. 
 
4.2 The Role of the Amygdala and CRIP1a in Anxiolytic-like Behavior. 
     By employing a loss-of-function approach, we have discovered a novel role of CRIP1a in 
anxiety-like behaviors.  Two different models were used to independently investigate anxiety-
like behavior in naïve CRIP1a WT and KO mice.  The first was the light:dark box assay, which is 
a one-time assessment (due to habituation) that tracks the animal’s movements between an open, 
brightly lit area and a dark, enclosed area, and sums the time spent in each compartment (for 
review, see Bourin and Hascoët, 2003).  Rodents, including mice, are expected to spend more 
time in the dark side due to their natural tendencies as prey animals to hide from predators out in 
the open. Therefore, any manipulation, whether it be biological or pharmacological, that leads to 
increased times in the light suggests an anxiolytic-like effect.  Studies have previously shown 
that this model can predict anxiolytic-like actions of drugs such as benzodiazepines and 
serotonergic (5HT1A) agonists (Crawley and Goodwin, 1980; Sanchez, 1995).  In our studies, 
naïve CRIP1a KO mice displayed an anxiolytic-like phenotype by spending more time in the light 
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side compared to their WT littermates.  CRIP1a WT behavior in the light:dark box was consistent 
with typical murine tendencies to remain in the dark, as reported in the literature (Crawley and 
Goodwin, 1980; Crawley and Davis, 1982).  It is important to note that this anxiolytic-like effect 
was not due to differences in locomotor activity or freezing behavior, as determined by video 
tracking software.  This finding is congruent with studies that pharmacologically targeted the 
endocannabinoid system with specific enzyme and uptake inhibitors, leading to reduced anxiety-
like behavior without alterations in motor activity or coordination (Patel and Hillard, 2006).  
Furthermore, our results are not likely due to strain influences, as the 129sv line and its 
substrains are particularly found to be anxiogenic when compared to other strains, including 
C57BL6/J.  This fact is important to consider given that our mice are on a hybrid background of 
C57BL6/J and 129sv lines, a result of the technique used to create this KO line.  The behavior 
observed in CRIP1a KO mice not only provides further insight into one functional role of CRIP1a, 
but also provides an additional line of support that altering the endocannabinoid system, 
particularly by increasing its activation, can lead to anxiolytic-like phenotypes.  This effect has 
been previously demonstrated genetically and pharmacologically, as FAAH KO mice or 
C57BL/6N WT mice treated with the FAAH inhibitor, URB597, have reportedly displayed 
anxiolytic-like behaviors in the elevated plus maze and light:dark box assays (Moeira et al. 
2008).  These relative increases in anandamide specifically, that lead to a reduced anxiety-like 
state, conveniently offer physiological support for its name, which was derived from the Sanskrit 
word for “bliss”.   
Since the mice can only be tested once in the light:dark box assay, we wanted to confirm this 
phenotype by testing mice in a second model capable of predicting anxiety-like behaviors: the 
marble burying assay.  Again, a robust anxiolytic-like phenotype was observed in CRIP1a KO 
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compared to WT mice.  Previous studies have investigated the role of the endogenous 
cannabinoid system in anxiety-like behaviors using the marble-burying assay and found that 
burying behavior was reduced after treatment with low doses (1 to 3 mg/kg) of cannabinoid 
agonists such as WIN or the FAAH inhibitors, URB597 and PF-3845 (Gomes et al. 2011; 
Kinsey et al. 2011).  The in vivo results observed in our CRIP1a KO mice could be explained by a 
possible increase in endocannabinoid signaling due to the lack of negative regulation of CB1 
receptors by CRIP1a.  Our findings, combined with current reports in the literature, further 
support an anxiolytic role for endogenous cannabinoid signaling.  Though it might seem unlikely 
that endocannabinoid ligands would be significantly altered by the loss of CRIP1a, 2-AG and 
anandamide levels have yet to be measured in CRIP1a KO mice.  It makes sense however, that 
without this negative regulatory protein present, endocannabinoids might be more effective at 
activating the CB1 receptor and thus eliciting behaviors such as this anxiolytic-like phenotype.  
Particular interest for future studies would include treating CRIP1a KO mice acutely with specific 
catabolic enzyme inhibitors for FAAH and MAGL using compounds such as URB597 and JZL-
184, respectively, as well as the new dual FAAH/MAGL enzyme inhibitor, JZL-185 (Long et al. 
2009).  Not only could these studies provide further insight into the role of, and alterations in 
endocannabinoid signaling in the absence of CRIP1a in vivo, but they might also pinpoint which, 
if either, ligand is primarily responsible for mediating the anxiolytic-like behaviors in CRIP1a 
KO mice.   
The ex vivo findings of significantly increased CB1 receptor-mediated G-protein activity 
within the amygdala of CRIP1a KO mice might also be playing a role in the observed anxiolytic-
like phenotype (Results 3.5).  These results showed that maximal activation of G-proteins by the 
synthetic cannabinoid agonist CP55,940 or the putative endocannabinoid NE was significantly 
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elevated in CRIP1a KO relative to WT mice.  Moreover, CB1 receptor expression was not altered 
in CRIP1a KO compared to WT mice in any of the regions examined, including the amygdala 
(Results 3.3).   Together, these data suggest that the increases in G-protein activity are not due to 
a greater density in CB1 receptors, but a greater signaling capacity of the available receptors.  
These data agree with our hypothesis that CB1 receptor levels would remain unaltered and 
agonist-stimulated G-protein activity would increase, based on previous studies in our laboratory 
where overexpression of CRIP1a did not affect CB1 receptor levels and attenuated agonist-
stimulated activity.  However, it is not completely certain whether enhanced CB1 receptor-
mediated G-protein activity in the amygdala is responsible for the anxiolytic-like phenotype seen 
in CRIP1a KO mice.  Future studies will need to determine involvement of CB1 receptors in this 
effect, for example, by administration of a CB1 antagonist such as SR141716A or by breeding of 
dual CB1 receptor/ CRIP1a null mice.  Moreover, local infusion of CB1 antagonist or siRNA-
mediated CB1 receptor knockdown in the amygdala could more selectively implicate altered CB1 
receptor signaling in this region as the mechanism of the anxiolytic-like phenotype. 
Most reports suggest that the amygdala does play a role in stress and anxiety-like behaviors, 
though it is largely thought to be involved in anxiogenic behaviors (Onaivi et al. 1995; Patel et 
al. 2004).  Observed in both animal models and humans, cannabinoid agonists produce bi-phasic 
effects with regard to anxiety in a dose-dependent manner, such that low doses are often 
anxiolytic, whereas higher doses are anxiogenic (Giuliani et al. 2000; Ashton, 1999).  Rubino et 
al. (2008) attempted to determine which brain regions were responsible for the anxiogenic- and 
anxiolytic-like behaviors elicited by centrally injecting varying doses of cannabinoids.  After 
administering low and high doses of THC directly into the basolateral amygdala of rats, results 
indicated that only one low dose (1 µg) elicited anxiogenic-like behaviors, while all other doses 
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produced no response.  Assuming our agonist-stimulated [35S]GTPγS binding results in the 
amygdala relate to and/or play a part in our findings in the marble burying and light:dark box 
assays, our data collectively suggest the opposite function of the amygdala with regard to 
cannabinoids and anxiety.  There is however, a notable species difference between rats and mice 
in regard to dose-sensitivity to cannabinoid agonists, as one study showed that the ED50 value of 
THC to induce anxiogenic-like behavior was three-fold lower in rats (Onaivi et al. 1990). 
It is also important to note that the amygdala can be distinctly separated into subregions, each 
of which provides specific projection pathways to other brain regions (Figure 33) and is 
comprised of different neuronal populations.  The basolateral amygdala (BLA) is primarily 
comprised of glutamatergic neurons, with estimates as high as 90%, whereas the central 
amygdala is reportedly comprised of 95% GABAergic medium spiny neurons (Tye et al. 2011; 
McDonald, 1982).  The central amygdala (CeA) is also the primary output region, projecting to 
the brainstem and thought to be responsible for mediating behavioral responses associated with 
anxiety and fear (Davis, 2000; Krettek and Price, 1978).  CB1 receptors are expressed on a subset 
of cholecystokinin-positive (CCK) GABAergic neurons as well as glutamatergic pyramidal 
neurons within the BLA (McDonald and Mascagni, 2001).  Activation of CB1 receptors within 
this region attenuates GABAergic and glutamatergic neurotransmission via presynaptic 
inhibition (Azad et al. 2003).  However, within the CeA, GABAergic transmission is not affected 
by CB1 receptor activation (Katona et al. 2001).  CB1 KO mice have been shown to exhibit 
anxiogenic behaviors in the elevated plus maze test by spending less time in the open arms of the 
apparatus (Haller et al. 2002).  Interestingly, this same study found that administration of 
SR141716A not only led to increases in anxiety-like behavior in WT mice, but also led to further 
increases in anxiety in CB1 KO mice, suggesting the presence of a possible novel receptor for 
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SR141716A that plays a role in anxiogenic-like behaviors.  Furthermore, CB1 KO mice did not 
exhibit any anxiolytic-like behaviors, which supports the argument that activation of the CB1 
receptor by endocannabinoids leads to anxiolytic-like behaviors and agrees with our findings in 
CRIP1a KO mice.  The role of CRIP1a in anxiolytic-like phenotypes is far from being completely 
understood, but offers a valuable new area of research regarding cannabinoids and anxiety-like 
behaviors.   
 
                   
Figure 32. A schematic adapted from Tye et al. (2011) displaying the subnuclei of the amygdala 
and their respective projections within the amygdala, as well as to other brain regions. Primary 
input is received by the lateral amygdala from the cortex and thalamus, while primary output is 
mediated by the central amygdala to the hypothalamus and hindbrain. CB1 receptors are highly 
expressed in the lateral and basal nuclei, while little-to-no expression is observed in the central 
and medial nuclei (Katona et al. 2001).   
 
 
4.3 CRIP1a and Nociception. 
 
     Naïve CRIP1a KO mice displayed significantly longer latencies in the warm water tail 
withdrawal test at 52ºC, however similar differences in nociceptive sensitivity were not observed 
at other temperatures (48ºC and 56ºC) or in other measures such as the hot plate assay at 52ºC 
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and 56ºC.  This restricted temperature range is not uncommon in mouse models of altered 
cannabinoid signaling, as Cravatt et al. (2001) found FAAH KO mice exhibited longer latencies 
in the hot plate assay at 56ºC only, but not at 54ºC or 58ºC.  The same study also showed FAAH 
KO mice exhibited longer latencies compared to WT mice in the warm water tail withdrawal 
assay at 56ºC.  These findings, along with our own results of antinociception in the CRIP1a KO 
mice, suggest that the endocannabinoid system plays a role in pain signaling pathways and thus 
pain thresholds.  However, it is important to note that although the warm water tail withdrawal 
assay is considered a spinal measure of antinociception (Franklin et al. 1989; Lichtman et al. 
1991), our [35S]GTPγS binding data revealed no significant differences in CB1 agonist-
stimulated G-protein activity within the spinal cord of CRIP1a WT and KO mice.  Thus, future 
studies using the antagonist, SR141716A, should be performed to determine whether the loss of 
CRIP1a affects spinally mediated nociception in a CB1 receptor-dependent manner.   
Stress-induced analgesia is a common caveat in behavioral tests requiring the mice to be 
handled and/or restrained, and has been shown to have an endocannabinoid-mediated mechanism 
(Connell et al. 2006; Kurrikoff et al. 2008).  Additionally, stress-induced analgesia may be a 
result of signaling pathways originating from the BLA (Connell et al. 2006).  As discussed 
earlier, this portion of the amygdala expresses high levels of CB1 receptors, and our [35S]GTPγS 
binding data showed increased CB1 agonist-stimulated G-protein activity in the amygdala of 
CRIP1a KO mice.  Therefore, the antinociception observed in CRIP1a KO mice could have been a 
result of a genotype-related difference in stress-induced analgesia and not due to the loss of 
CRIP1a in the spinal cord.  While this is a possible interpretation, it is important to recognize that 
the projections from the BLA primarily terminate in the PAG, though some reports suggested 
projections could terminate in the dorsal horn of the spinal cord (Kurrikoff et al. 2008; Walker 
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and Hohmann, 2005).  However, central administration of CP55,940 into the PAG has been 
shown to elicit antinociceptive effects in the tail-flick test in rats (Lichtman et al. 1996).  We did 
not find a main effect of genotype in either baseline latencies (see Results 3.8) or latencies after 
CP55,940 administration (see Figure 26) in the hot plate assay, in which the PAG is also thought 
to play a role.  Perhaps there are species differences regarding dose-sensitivity between rats and 
mice within the PAG, as there are in the amygdala, which could explain the lack of effects 
observed in CRIP1a KO mice.  Furthermore, the PAG has yet to be investigated in CRIP1a KO 
mice, and assessments of both CB1 receptor saturation binding and agonist-stimulated 
[35S]GTPγS binding should be performed in the future to determine whether loss of CRIP1a 
affects CB1 receptor expression or G-protein activation within the PAG.   
 
4.4 Implications That Expression of CB1 Receptors Is Independent of CRIP1a Expression 
and Vice Versa.  
     We examined the cerebellum, hippocampus and amygdala of CRIP1a KO mice for alterations 
in CB1 receptor expression by performing [3H]CP55,940 saturation binding assays.  CB1 receptor 
expression, as determined by [3H]CP55,940 Bmax values, was found to not differ from that of 
CRIP1a WT mice in all regions examined (see Results 3.3).  Our findings confirm that alterations 
in CRIP1a expression do not affect CB1 receptor levels, as previous reports showed that over-
expression of CRIP1a also did not affect CB1 receptor expression (Niehaus et al. 2007).  It should 
be noted that these studies reflect total receptor levels, since the assays are performed in total 
membrane fractions that were isolated by high-force centrifugation (at 50,000 x g) from tissue 
homogenates, and do not reflect changes in subcellular localization of receptors.  Therefore, even 
though no differences have been detected in our receptor saturation binding assays thus far, there 
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could still be differences in CB1 receptor densities at the plasma membrane in vivo and/or 
possible alterations in receptor internalization patterns within these regions that could result in 
altered CB1 receptor signaling.    
We also investigated CRIP1a expression in the cerebellum, prefrontal cortex and amygdala of 
CB1 WT and KO mice after repeated vehicle and THC treatments.  Since we had established that 
CB1 receptor expression was not altered after either the loss or over-expression of CRIP1a, this 
study was important to show the relationship between the loss of CB1 receptors and CRIP1a 
expression, as well as the effects of prolonged THC treatment on CRIP1a expression, both in the 
presence and absence of CB1 receptors.  After Western immunoblots were analyzed, we found 
that neither the loss of CB1 receptors, nor the prolonged activation of CB1 receptors affects 
CRIP1a expression (see results 3.12).  This study provided a first examination of whether chronic 
THC administration could directly affect CRIP1a expression, by analyzing THC-treated Cnr1 
WT and KO mice.  In each of these cases, the results showed no significant differences in CRIP1a 
expression among treatments and genotypes.  The fact that CRIP1a expression was not affected 
by any of these perturbations in CB1 receptor expression or function could suggest an 
interpretation that CRIP1a has important roles in addition to negatively regulating the CB1 
receptor.  Other receptor systems were not examined in these studies, but future studies should 
investigate alterations in receptors such as dopamine D2 receptors.  Previous reports suggested 
that alterations in CB1 and D2 receptor expression within the striatum inversely affected CRIP1a 
expression, such that when the expression of these receptors was reduced, CRIP1a expression 
increased, and vice versa (Blume et al. 2013).  Since the striatum was not investigated in our 
studies, we do not yet know whether genetic disruption of CB1 receptors or CRIP1a can alter each 
other’s expression in this brain region.  However, future experiments could be performed to 
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determine whether alterations in CB1 receptor expression or activation can affect CRIP1a 
expression, or if CRIP1a deletion affects CB1 receptor expression or activity, in the striatum and 
other CNS regions not examined in the present studies.  
 
4.5 Interpretations for the Lack of Effects in the Cerebellum and Hippocampus After 
Global, Life-Long Absence of CRIP1a.  
     Our [35S]GTPγS binding results indicated no differences between CRIP1a WT and KO mice in 
the cerebellum, hippocampus or spinal cord.  This result was supported by in vivo evidence 
gathered by testing CRIP1a WT, HET and KO mice in a cumulative dosing tetrad assessment 
with CP55,940, where no significant differences were observed.  The results obtained were not 
expected, as our hypothesis was that CRIP1a KO mice might exhibit exaggerated responses to 
cannabinoid agonists in CNS regions where CB1 receptors and CRIP1a are co-distributed.  
Though we did not evaluate behaviors known to involve the hippocampus, such as learning and 
memory, we were somewhat surprised that loss of CRIP1a did not affect agonist-stimulated G-
protein activity given previous results obtained in autaptic hippocampal neurons, which showed 
that over-expression of CRIP1a attenuated 2-AG-mediated DSE and decreased inhibition of 
excitatory post-synaptic currents.  However, if CB1 receptors and CRIP1a are not normally 
expressed in the same cells or subcellular elements in the hippocampus, this could potentially 
explain the lack of effect of CRIP1a KO on CB1 receptor-mediated G-protein activation.  
The fact that CB1 agonist-stimulated G-protein activity did not differ between CRIP1a WT 
and KO mice within the cerebellum could offer some explanation for the lack of effects of 
genotype on motor activity and RotaRod performance, but [35S]GTPγS binding experiments need 
to be performed in the striatum of all genotypes in order to gain a better understanding of how 
	  	   99 
these particular motor behaviors might be affected by deletion of CRIP1a.  An analysis of the 
fitted curves in Figure 13 showed that the KO mice display slightly less G-protein activity in the 
cerebellum in response to CP55,940, which was significant by two-way ANOVA.  One 
interpretation could be that a greater fraction of CB1 receptors were uncoupled from G-proteins 
due to prolonged over-activation of CB1 receptors in CRIP1a KO mice, which might account for 
the results we observed.  Studying the CRIP1a HET mice in more detail will be a valuable tool in 
determining how a reduction in CRIP1a expression affects the system compared to a complete 
abolishment as seen in the KO mice.  Different results could be obtained in HET mice because 
less compensation might be expected to occur relative to KO mice.  If CRIP1a KO mice 
experience a global, life-long abolishment of CRIP1a, it is possible that CB1 receptors are 
continuously dysregulated and over-active in some brain regions.  Often times, the cell 
compensates for this over-activation by increasing receptor internalization and desensitization.  
We know that CRIP1a KO mice are not exhibiting CB1 receptor downregulation, as shown by our 
[3H]CP55,940 saturation binding results.  However, what we do not know is the subcellular 
localization of these receptors in vivo.  There is evidence to suggest that knock-down of CRIP1a 
in the N18TG2 cell line increases CB1 receptor densities at the plasma membrane, while over-
expression of CRIP1a leads to increased CB1 receptor internalization, as determined by co-
immunoprecipitation studies (Blume et al. 2013a).  It is possible that CRIP1a KO mice may 
initially exhibit greater CB1 receptor densities at the plasma membrane, and thus potentially be 
subjected to increased activation via endocannabinoids, and eventually, desensitization and 
internalization.  The same study also found that exposure to WIN led to CB1 receptor 
internalization in both control and CRIP1a knock-down cells, while receptor externalization was 
observed in the CRIP1a over-expressing cells.  This effect could explain why under agonist-
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stimulated conditions, both in vivo and ex vivo, we did not see any genotype-related differences 
in regions such as the cerebellum.  Since these studies were performed in a cell line, which does 
not exactly replicate in vivo conditions, similar studies should be repeated in various brain 
regions of CRIP1a WT and KO mice to reveal effects on CB1 receptor trafficking patterns that 
result from the loss of CRIP1a.  However, such experiments would be difficult to perform 
because CB1 receptors are largely localized on axonal projections and terminals, so CB1 receptor 
subcellular localization would have to be studied using electron microscopy.  Furthermore, 
temporally controlled conditional CRIP1a KO mice could be developed to reduce the potential for 
compensation in specific brain regions.  In addition, in vivo tools such as central injections of 
siRNA could aid in determining the effects of CRIP1a knockdown, but not deletion, in specific 
brain regions, thus providing a complementary approach to investigating CRIP1a functions when 
compared to observing the CRIP1a HET mice we possess currently.  
     Though there is some evidence of CRIP1a and CB1 receptor co-localization within the 
cerebellum on granule cell terminals (K. Sayers and D.E. Selley, unpublished results), other 
regions have not yet been investigated.  It should be noted that while some regions have been 
shown to express both CRIP1a and CB1 receptors, such as the prefrontal cortex and the 
hippocampus, perhaps these two do not co-localize in the same cells.  Cellular trafficking of 
CRIP1a has not been well established and it is possible that CB1 receptors and CRIP1a are not 
distributed the same area of the cell, even where they are co-expressed by the same cells.  Future 
studies should examine various brain regions for evidence of CRIP1a:CB1 receptor co-
localization.  In particular, the amygdala (where we did observe genotype-related differences) 
and hippocampus (where we did not observe any differences between genotypes) should be 
investigated to unmask possible explanations for the opposite results observed in our studies.   
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     Lastly, the possibility of redundancy should not be dismissed.  The existence of CRIP1a, and 
one of its known functions, was discovered somewhat indirectly by earlier studies conducted by 
Nie and Lewis (2001) that focused on mutational analysis of the CB1 receptor.  When an 
alteration in CB1 receptor function was observed after deleting a portion of the C-terminus, the 
search for a regulatory protein was initiated.  It is possible that an as yet undiscovered protein 
exists in mice that is capable of producing similar functions to CRIP1a.  If this is the case, 
perhaps it is only expressed in specific brain regions or co-localized with CB1 receptors in 
particular regions, accounting for a subset of our results where we did not observe significant 
differences between genotypes.  Although the initial yeast two-hybrid screening results did not 
reveal additional proteins that bound to distal C-terminus of the CB1 receptor (Niehaus et al. 
2007), it does not eliminate the possibility that another protein could bind to another intracellular 
portion of the CB1 receptor and elicit effects that mimic CRIP1a function.  
 
4.6 Interpretation of the Lack of Effects of CRIP1a KO on SR141716A-Mediated Inhibition 
of [35S]GTPγS Binding in the CNS. 
     We did not observe substantial constitutive CB1 receptor activity in either CRIP1a WT or KO 
mice using a single concentration of SR141716A that was found to be maximally effective to 
inhibit constitutive CB1 receptor activity in cell lines.   Because CRIP1a inhibits constitutive CB1 
receptor activity in cell models, we predicted enhanced constitutive activity of CB1 receptors in 
multiple brain region of CRIP1a KO mice, which would be observed by greater SR141716A-
mediated inhibition of [35S]GTPγS binding.  In the cerebellum, modest SR141716A-mediated 
inhibition was seen, but did not differ WT and KO mice.  These results are consistent with the 
lack of effect of CRIP1a deletion on agonist-stimulated G-protein activity in this region.  
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However, inhibition of basal [35S]GTPγS binding by this inverse agonist was minimal or not 
observed in other CNS regions, including amygdala, hippocampus and spinal cord.  These results 
were essentially consistent with previous studies, as constitutive activity of cannabinoid 
receptors has traditionally been difficult to measure in the brain.  Cerebellar homogenates from 
rat brain have been investigated in search of constitutively active CB1 receptors, but the results 
indicated that the inhibitory actions of SR141716A were maximal at µM concentrations, and 
were therefore either not CB1 receptor-mediated or were mediated by allosteric site on CB1 
receptors (Sim-Selley et al. 2001).  The finding that significant inhibition of basal [35S]GTPγS 
binding was not seen at inverse agonist concentrations that antagonized CB1 agonist-induced 
activity suggest that CB1 receptor constitutive activity in these membranes was not detectable 
under the conditions of the [35S]GTPγS binding assay.  In fact, µM concentrations of 
SR141716A have also been shown to exhibit inhibitory effects on basal [35S]GTPγS binding 
even in CB1 receptor KO mice (Breivogel et al. 2001), further suggesting that these 
concentrations are not relevant for measuring inhibition of CB1 receptor-mediated activity.  
Thus, our results further indicate that constitutive CB1 receptor activity is minimal or that the 
[35S]GTPγS approach is not optimal for evaluating constitutive activity of CB1 receptors in the 
brain. 
4.7 Conclusions.  
     The results gathered in this thesis have revealed important and novel information regarding 
CRIP1a by employing a loss of function model through a new knockout mouse line.  Our data 
provide new lines of evidence that CRIP1a, a putative new member of the endogenous 
cannabinoid system, plays an essential role in anxiety-like phenotypes.  The data also revealed 
that the previously determined role of CRIP1a, to negatively regulate CB1 receptor-mediated G-
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protein signaling was upheld by our [35S]GTPγS binding results in the amygdala of CRIP1a KO 
mice, which revealed increased agonist-stimulated G-protein activity.  Whether this enhancement 
of CB1 receptor signaling in the amygdala is responsible for the anxiolytic-like phenotype that 
was observed in CRIP1a KO mice in vivo is a matter to be resolved by future research.  In 
addition, we have shown that the expression of CRIP1a and CB1 receptors is independent of one 
another in brain regions investigated thus far.  We now have a greater appreciation for the 
potential roles of CRIP1a in vivo, as our studies were the first investigation of CRIP1a function to 
be performed in live animals.  Our exciting findings suggest that CRIP1a could be a key player in 
the endocannabinoid system and could serve as a promising future pharmacological target for 
studying and treating anxiety disorders. 
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